Document:

EX-10.16

 Exhibit 10.16 

Execution Version 

Confidential 
 Certain
identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder
identified by the mark “[***]”. 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

by and between 
 Spark
Therapeutics, Inc. 
 and 

Senti Biosciences, Inc. 

Effective April 9, 2021 
  

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1
	 	DEFINITIONS	  	 	1	 
			
	 ARTICLE 2
	 	OVERVIEW AND GOVERNANCE	  	 	13	 
			
	 2.1
	 	Overview of Research Collaboration	  	 	13	 
			
	 2.2
	 	Joint Research Committee	  	 	13	 
			
	 2.3
	 	Joint Project Team	  	 	15	 
			
	 2.4
	 	Joint Patent Working Group	  	 	16	 
			
	 2.5
	 	Alliance Managers	  	 	16	 
			
	 2.6
	 	Co-Chairs	  	 	16	 
			
	 2.7
	 	Minutes and Reports	  	 	16	 
			
	 2.8
	 	Information and Results	  	 	17	 
			
	 ARTICLE 3
	 	RESEARCH PROGRAM	  	 	17	 
			
	 3.1
	 	Overview	  	 	17	 
			
	 3.2
	 	Research Plan	  	 	17	 
			
	 3.3
	 	Recordkeeping	  	 	17	 
			
	 3.4
	 	Subcontracts	  	 	17	 
			
	 3.5
	 	Performance; Funding	  	 	18	 
			
	 3.6
	 	Provision of, Use and Return of Spark Materials	  	 	18	 
			
	 3.7
	 	[***]	  	 	18	 
			
	 3.8
	 	Results Reporting; [***] and Selection of Option Promoters	  	 	19	 
			
	 ARTICLE 4
	 	EVALUATION PROGRAM; OPTION RIGHTS	  	 	19	 
			
	 4.1
	 	Evaluation Program	  	 	19	 
			
	 4.2
	 	Spark Option	  	 	20	 
			
	 4.3
	 	Provision of, Use and Return of Senti Materials	  	 	21	 
			
	 ARTICLE 5
	 	LICENSE GRANTS	  	 	22	 
			
	 5.1
	 	License Grants to Spark	  	 	22	 
			
	 5.2
	 	No Implied Rights; Negative Covenant	  	 	22	 
			
	 5.3
	 	License Grant to Senti	  	 	22	 
			
	 5.4
	 	Sublicensing Rights	  	 	23	 
			
	 5.5
	 	In-Licensed Technology	  	 	23	 
			
	 5.6
	 	Section 365(n) of the Bankruptcy Code	  	 	24	 

  
 - i - 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 ARTICLE 6
	 	DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION	  	 	24	 
			
	 6.1
	 	Development, Manufacture and Commercialization of Products	  	 	24	 
			
	 6.2
	 	Regulatory Activities	  	 	24	 
			
	 6.3
	 	Diligence	  	 	25	 
			
	 6.4
	 	Regulatory Assistance	  	 	25	 
			
	 6.5
	 	Compliance	  	 	25	 
			
	 ARTICLE 7
	 	CONSIDERATION	  	 	25	 
			
	 7.1
	 	[***]	  	 	25	 
			
	 7.2
	 	Research Support	  	 	25	 
			
	 7.3
	 	License Fee	  	 	26	 
			
	 7.4
	 	Development Milestone Payments	  	 	26	 
			
	 7.5
	 	Commercial Milestone Payments	  	 	27	 
			
	 7.6
	 	Royalties	  	 	27	 
			
	 7.7
	 	Reports and Payments	  	 	27	 
			
	 7.8
	 	Payment Method; Late Payments	  	 	28	 
			
	 7.9
	 	Currency	  	 	28	 
			
	 7.10
	 	Taxes	  	 	28	 
			
	 7.11
	 	Maintenance of Records	  	 	28	 
			
	 7.12
	 	Audits	  	 	29	 
			
	 ARTICLE 8
	 	INTELLECTUAL PROPERTY MATTERS	  	 	29	 
			
	 8.1
	 	Ownership	  	 	29	 
			
	 8.2
	 	Prosecution and Maintenance of Patents	  	 	31	 
			
	 8.3
	 	Defense of Third Party Infringement Claims	  	 	32	 
			
	 8.4
	 	Enforcement of Spark Responsibility Patents	  	 	32	 
			
	 8.5
	 	Other Enforcement of Actions	  	 	32	 
			
	 8.6
	 	Cooperation	  	 	33	 
			
	 8.7
	 	Recoveries	  	 	33	 
			
	 ARTICLE 9
	 	CONFIDENTIALITY	  	 	34	 
			
	 9.1
	 	Treatment of Confidential Information	  	 	34	 
			
	 9.2
	 	Exceptions	  	 	35	 
			
	 9.3
	 	Disclosures by Law	  	 	35	 
			
	 9.4
	 	Publication Rights	  	 	35	 
			
	 9.5
	 	Return of Confidential Information	  	 	36	 
			
	 9.6
	 	Press Release; Terms of this Agreement; Use of Names	  	 	37	 

  
 - ii - 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 ARTICLE 10
	 	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	 	38	 
			
	 10.1
	 	Mutual Representations and Warranties	  	 	38	 
			
	 10.2
	 	Mutual Covenants of the Parties	  	 	38	 
			
	 10.3
	 	Senti’s Representations and Warranties	  	 	38	 
			
	 10.4
	 	Senti’s Covenants	  	 	39	 
			
	 10.5
	 	No Other Warranties	  	 	39	 
			
	 ARTICLE 11
	 	INDEMNIFICATION, INSURANCE AND RELEASE	  	 	40	 
			
	 11.1
	 	Indemnification by Spark	  	 	40	 
			
	 11.2
	 	Indemnification by Senti	  	 	40	 
			
	 11.3
	 	Procedure	  	 	40	 
			
	 11.4
	 	No Consequential Damages	  	 	41	 
			
	 11.5
	 	Insurance	  	 	41	 
			
	 ARTICLE 12
	 	TERM AND TERMINATION	  	 	41	 
			
	 12.1
	 	Term	  	 	41	 
			
	 12.2
	 	Termination	  	 	41	 
			
	 12.3
	 	Effects of Termination	  	 	42	 
			
	 12.4
	 	Accrued Obligations	  	 	43	 
			
	 12.5
	 	Survival	  	 	43	 
			
	 12.6
	 	Non-exclusive Remedy	  	 	43	 
			
	 ARTICLE 13
	 	DISPUTE RESOLUTION	  	 	44	 
			
	 13.1
	 	Governing Law; Jurisdiction; Waiver of Jury Trial	  	 	44	 
			
	 13.2
	 	Dispute Resolution	  	 	44	 
			
	 13.3
	 	Equitable Relief	  	 	44	 
			
	 ARTICLE 14
	 	MISCELLANEOUS	  	 	44	 
			
	 14.1
	 	Waiver	  	 	44	 
			
	 14.2
	 	Rights Cumulative	  	 	45	 
			
	 14.3
	 	Notices	  	 	45	 
			
	 14.4
	 	Entire Agreement; Amendment	  	 	46	 
			
	 14.5
	 	Severability	  	 	46	 

  
 - iii - 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 14.6
	 	Assignment	  	 	46	 
			
	 14.7
	 	Counterparts	  	 	46	 
			
	 14.8
	 	Force Majeure	  	 	47	 
			
	 14.9
	 	Third Party Beneficiaries	  	 	47	 
			
	 14.10
	 	Relationship of the Parties	  	 	47	 
			
	 14.11
	 	Performance by Affiliates	  	 	47	 
			
	 14.12
	 	Export Control	  	 	47	 
			
	 14.13
	 	Construction	  	 	48	 

 Exhibits 
  

			
	Exhibit A:	  	Option Field
	Exhibit B:	  	Promoter Profiles
	Exhibit C:	  	Research Plan
	Exhibit D:	  	[***]
	Exhibit E:	  	Materials Transfer Letter
	Exhibit F-1:	  	Senti Press Release
	Exhibit F-2:	  	Spark Press Release
	Exhibit G:	  	Data Package Template

  
 - iv - 

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (“Agreement”), dated as of April 9, 2021 (the “Effective
Date”), is entered into by and between Senti Biosciences, Inc., a Delaware corporation, with offices at 2 Corporate Drive, South San Francisco, CA 94080 (“Senti”), and Spark Therapeutics, Inc., a Delaware corporation, with
offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Spark”). 
 WHEREAS, Spark is a biopharmaceutical
company specializing in the development of gene therapy products. 
 WHEREAS, Senti leverages its proprietary technologies to design, build
and test gene circuits for various uses, including use in gene therapy products. 
 WHEREAS, the Parties desire to enter into an exclusive
arrangement for a research collaboration, pursuant to which Senti will apply the Senti Technology to design, build and test Synthetic Promoters (as defined below) that are intended to have a given Promoter Profile (as defined below) for further
evaluation by Spark (the “Collaboration”), and under which Spark will be granted an exclusive option to obtain a worldwide, exclusive license to the resulting Option Promoters (as defined below) from the Collaboration for use in
in vivo gene therapy products for specified indications, all subject to the terms and conditions set forth herein. 
 NOW, THEREFORE,
in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Senti and Spark agree as follows: 

ARTICLE 1 
 DEFINITIONS

 General. When used in this Agreement, each of the following terms shall have the meanings set forth in this Article 1:

 1.1 “Accounting Standards” means United States Generally Accepted Accounting Principles (GAAP) or International Financial
Reporting Standards (IFRS), in each case as then current at the relevant time and as consistently applied by the applicable Person. 

“Affiliate” means, with respect to a Person, any other Person directly or indirectly controlled by (which controlled Person is hereby defined
to be a “Subsidiary” of such Person), controlling (which controlling Person is hereby defined to be a “Parent” of such Person), or under common control with, such Person. For purposes of this definition,
“control” means: (a) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign Person in a particular jurisdiction) of the voting share
capital in a Person; or (b) possession, directly or indirectly, of the power to direct the management and policies of a Person, whether through ownership of voting securities, by contract relating to voting rights or corporate governance or
otherwise. [***]. 

  
 - 1 - 

 1.2 “BLA” means a Biologics License Application, or any supplement to such
application, as defined in the U.S. Federal Food, Drug, and Cosmetic Act (“FDCA”), as amended, and applicable regulations promulgated thereunder by the FDA. 

1.3 “Business Day” means a day other than (a) a Saturday or a Sunday, or (b) a day on which banking institutions in
Philadelphia, PA or San Francisco, CA are authorized or required by Law to remain closed. 
 1.4 “Calendar Quarter” means
each of the three (3) month periods ending on March 31, June 30, September 30 and December 31 of any year; provided, that the first Calendar Quarter under this Agreement will be the period beginning on the Effective
Date and ending at the end of the Calendar Quarter in which the Effective Date is encompassed and the last Calendar Quarter of the Term will be the period beginning on the beginning of the Calendar Quarter in which the effective date of termination
or expiration is encompassed and ending on the effective date of expiration or termination of this Agreement. 
 1.5 “Calendar
Year” means each twelve (12) month period commencing on January 1, and ending on December 31; provided, that the first Calendar Year under this Agreement will be the period beginning on the Effective Date and ending at the
end of the Calendar Year in which the Effective Date is encompassed and the last Calendar Year of the Term will be the period beginning on January 1 and ending on the effective date of expiration or termination of this Agreement. 

1.6 “Change of Control” means, with respect to a Party, (a) a merger, reorganization, combination or consolidation of
such Party with a Third Party that results in the holders of beneficial ownership of the voting securities or other voting interests of such Party (or, if applicable, the ultimate Parent of such Party) immediately prior to such merger,
reorganization, combination or consolidation ceasing to hold beneficial ownership of greater than fifty percent (50%) of the combined voting power of the surviving entity or the ultimate Parent of the surviving entity immediately after such merger,
reorganization, combination or consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner of more than fifty percent (50%) of the combined voting power
of the outstanding securities or other voting interest of such Party, or (c) the sale, lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) to a Third Party of all or substantially all of such
Party’s assets. 
 1.7 “Claim” means any demand, claim, action, suit, proceeding, order, investigation, finding or
verdict (in contract, tort or otherwise). 
 1.8 “Clinical Trial” means a human clinical trial or human clinical
investigation of a product in any country. 
 1.9 “Commercialization” and “Commercialize” means all pre-launch, launch or post-launch activities undertaken relating to the marketing, promotion, offering for sale, importation, distribution or sale of a product, including advertising, promotion, strategic marketing,
market research, sales force recruitment, training, sales meetings, detailing, sample drops; activities related to national accounts, managed care accounts and other similar accounts and government programs; activities related to reimbursement,
advertising, market and product support; customer service, medical support, educational initiatives, commercial compliance programs, product storage and distribution, order entry, billing, collection, invoicing, returns; other marketing, sales and
distribution activities; and regulatory affairs related to all of the foregoing. 

  
 - 2 - 

 1.10 “Commercially Reasonable Efforts” means, (a) with respect to
Spark’s obligation to Develop and Commercialize Products, such level of efforts and resources normally used by [***] for a product that is of similar market potential at a similar stage in its development or product life, taking into account
all relevant factors, including [***] and (b) with respect to a Party’s performance of any other obligations under this Agreement, the carrying out of such obligations in a reasonable, diligent and good faith manner using at least the
level of efforts such Party would normally use in its performance of a similar activity for its own account. For purposes of clarity, Commercially Reasonable Efforts will be determined [***] within the Territory, and it is anticipated that [***].

 1.11 “Confidential Information” means any information disclosed, directly or indirectly, in any form whatsoever by or on
behalf of one Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) or its Affiliates, including the content of the transactions contemplated herein, all technology Controlled by the Disclosing
Party and any improvements thereto, any information relating to a Party’s or its Affiliates’ interests, business, finances, products, operations, sales, marketing, customers, suppliers and suppliers’ bills of materials, trade secrets,
Know-How, sequences, data, processes, methods, techniques, formulas, test data, presentations, analyses, studies, patent applications (as long as unpublished or undisclosed), financial data, product
development, assays, strategic and market research information, other relevant marketing information, clinical data and any other information, whether developed in connection with this Agreement or not, in each of the foregoing cases to the extent
disclosed by or on behalf of the Disclosing Party to the Receiving Party or its Affiliates pursuant to this Agreement or the Confidentiality Agreement. 

1.12 “Confidentiality Agreement” means the Mutual Confidentiality Agreement entered into by and between Spark and Senti, dated
[***]. 
 1.13 “Control” or “Controlled” means, with respect to any Patent Right, Know-How, Regulatory Material, Regulatory Approval, data, document, or other information, and with respect to any Person, possession (whether by ownership or license, other than a license or sublicense granted
pursuant to this Agreement) by such Person of the ability to grant an assignment, license, sublicense or access as provided for herein without [***]. Notwithstanding the foregoing, in the event that [***], the following shall be deemed to be [***]:

 (a) any Patent Right, Know-How, Regulatory Material, or Regulatory Approval [***]; and 

(b) any Patent Right, Know-How, Regulatory Material, or Regulatory Approval [***]; 

except, in each case ((a) and (b)), to the extent that any such Patent Right, Know-How, Regulatory Material, or
Regulatory Approval [***]. 
 1.14 “Counterparts” means: 

  
 - 3 - 

 1.15.1 with respect to a patent, the following items, collectively: any patent applications
from which such patent issued, and all patents and patent applications described in Section 1.15.2 with respect to each such patent application; and 

1.15.2 with respect to a patent application (including any provisional or utility application), the following items, collectively: (a) all
divisionals, continuations and continuations-in-part of such patent application (to the extent directed to subject matter described in any such patent application); (b)
any patents (including certificates of correction) issuing from such patent application or any patent application described in clause (a); (c) all patents and patent applications based on, corresponding to or claiming the priority date(s) of such
patent application or any of the patents or patent applications described in clauses (a) or (b); (d) any substitutions, extensions (including supplemental protection certificates), registrations, confirmations, reissues, re-examinations and renewals of any of the patents described in clauses (b) or (c); and (e) foreign counterparts of any of the foregoing. 

1.15 “Cover”, “Covering” or “Covered” means, with respect to a molecule or product, that,
but for a license granted to a Person under a claim included in Patent Rights, the Development, Manufacture, Commercialization or other exploitation of such molecule or product by such Person would infringe, or contribute to, or induce the
infringement of, such claim; it being understood that, with respect to a claim within a pending patent application, such pending claim shall be treated as if such pending claim were issued at the applicable time in its then-current form. 

1.16 “Debarred” means, with respect to a Person, that such Person (a) is debarred by the FDA pursuant to Section 306
of the FDCA, or is the subject of a conviction described in such section (or subject to a similar sanction of any other applicable Regulatory Authority), (b) is the subject of an FDA debarment investigation or proceeding (or similar proceeding of
any other applicable Regulatory Authority), or (c) has been charged with or convicted under U.S. Law for conduct relating to the development or approval, or otherwise relating to the regulation, of any product under the Generic Drug Enforcement
Act of 1992. 
 1.17 “Development” and “Develop” means, with respect to a molecule or product, all
activities relating to discovery, evaluation, research, preclinical, non-clinical and clinical development activities or pre-marketing activities, including:
identification of potential candidates, synthesis and testing by in vitro or in vivo assays, conducting toxicology studies, drug metabolism and pharmacokinetics studies, process and drug product (i.e., dosage form)
development, delivery system development, statistical analysis and report writing, Clinical Trials for the purpose of obtaining or maintaining Regulatory Approval, and regulatory affairs related to all of the foregoing. 

1.18 “[***]” means, with respect to [***]. 

1.19 “Dollar” or “$” means the legal currency of the United States. 

1.20 “EMA” means the European Medicines Agency and any successor agency thereto. 

1.21 “Encumbrance” means any claim, charge, equitable interest, hypothecation, lien, mortgage, pledge, license, option,
assignment to a Third Party, power of sale, retention of title by a Third Party, right of pre-emption, right of first refusal, or security interest of any kind, in each case, that [***]. 

  
 - 4 - 

 1.22 “EU5” means the United Kingdom, France, Germany, Italy and Spain. 

1.23 “European Union” means (a) all countries officially recognized as member states of the European Union as of the
Effective Date or at the time in question and (b) the United Kingdom, regardless of whether it is a member state of the European Union or not. 

1.24 “Executive Officer” means, with respect to either Party, the [***] of such Party, or [***]. 

1.25 “FDA” means the United States Food and Drug Administration and any successor agency thereto. 

1.26 “First Commercial Sale” means, with respect to a Product in a country in the Territory, the first sale of such Product by
Spark, any of its Affiliates or any Sublicensee to an unrelated Third Party for use or consumption of such Product in such country in the Licensed Field. [***] shall not be considered a First Commercial Sale. 

1.27 “FTE Rate” means a rate of [***] per annum based on the yearly time for a full-time equivalent scientific employee during
the Research Term, consisting of a total of [***] hours per annum (“FTE”), to be pro-rated on a daily basis if necessary; provided, that such rate shall be [***]. For the avoidance of
doubt: (i) such rate includes all benefits, travel, and overhead expenses; and (ii) in no event shall any one (1) individual be counted as more than one (1) FTE. Commencing on [***], the FTE Rate shall be [***]. 

1.28 “GCP” means all applicable current Good Clinical Practice standards for the design, conduct, performance, monitoring,
auditing, recording, analyses and reporting of Clinical Trials, including, as applicable, (a) as set forth in the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
(“ICH”) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products in the Territory, (b) the Declaration of Helsinki
(2004) as last amended at the 52nd World Medical Association in October 2000 and any further amendments or clarifications thereto, (c) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56 (Institutional
Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (d) the equivalent applicable Laws in any relevant country, each as may be amended and applicable from time to time and in each case, that
provide for, among other things, assurance that the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects. 

1.29 “GLP” means all applicable current standards for laboratory activities for pharmaceuticals, as set forth in the
FDA’s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58, and such standards of good laboratory practice as are required by the European Union and other organizations and governmental agencies in countries in which a Product
is intended to be sold, to the extent such standards are not less stringent than United States Good Laboratory Practice. 

  
 - 5 - 

 1.30 “Governmental Authority” means any federal, national, multinational,
state, provincial, country, city or local government or any court, arbitrational tribunal, administrative agency or commission or government authority acting under the authority of any federal, national, multinational, state, provincial, country,
city or local government. 
 1.31 “IND” means an Investigational New Drug Application filed with the FDA in the United
States or any equivalent counterpart in any country other than the United States, including all supplements and amendments thereto. 
 1.32
“IND Acceptance” means[***]. 
 1.33 “Indemnitee” means (a) with respect to Senti as the indemnified
Party, each Senti Indemnitee, and (b) with respect to Spark as the indemnified Party, each Spark Indemnitee. 
 1.34
“Initiation” means[***]. 
 1.35 “Know-How” means any
tangible or intangible information, inventions, know-how, data or materials, whether patentable or not, including (a) ideas, discoveries, improvements or trade secrets, (b) pharmaceutical, chemical
and biological materials, molecules, products, cell lines, compositions and sequences, (c) tests, assays, techniques, methods, procedures, formulas, formulations or processes, (d) technical, medical, clinical, toxicological, and other data
and other information relating to any of the foregoing, including preclinical and clinical data, (e) devices and (f) drawings, plans, designs, diagrams, sketches, specifications, or other documents containing or relating to such
information, inventions, know-how, data or materials; but excluding Patent Rights. 
 1.36
“Law” means any law, statute, rule, regulation, ordinance, court or administrative order, or other pronouncement having the effect of law, of any Governmental Authority that is applicable to a Party, this Agreement or any of the
activities contemplated hereunder. 
 1.37 “Licensed Field” means, with respect to a Licensed Promoter, the cure, treatment,
palliation, prevention or diagnosis of those indications set forth on Exhibit A that are identified by Spark in the Option Exercise Notice for such Licensed Promoter. 

1.38 “Licensed Promoter” means (a) an Option Promoter for which Spark has timely exercised a Spark Option or (b) [***] of
such Option Promoter. 
 1.39 “Losses” means losses, damages, judgments, penalties, fines, costs, expenses (including
reasonable attorneys’ or accountants’ fees, witness fees and expert fees and other expenses of litigation) and, subject to Section 11.3, amounts paid in settlement. 

1.40 “MAA” means a Marketing Authorization Application filed with the EMA, or any equivalent filing in any European country or
any other Regulatory Authority in any jurisdiction other than the U.S., seeking Regulatory Approval of a product. 
 1.41
“Manufacture” or “Manufacturing” means all activities related to the manufacturing of a molecule or product, including test method development and stability testing, formulation, process development, manufacturing scale-up, validation, manufacturing for use in non-clinical and clinical studies, manufacturing for commercial sale, fill/finish, packaging, labeling, release of product,
quality assurance/quality control development, quality control testing 
 (including in-process, in-process release and stability testing), shipping and storage of molecule or product or any component or ingredient thereof, and regulatory activities related to all of the foregoing. 

  
 - 6 - 

 1.42 “[***]” means [***]. 

1.43 “Milestone Event” means a milestone event described in Section 7.4 or
Section 7.5. 
 1.44 “Net Sales” means, with respect to Spark or any of its Affiliates or any
Sublicensees (each, a “Selling Party”), the gross amount invoiced by such Selling Party for sale or other commercial disposition of units of a Product for use by a Third Party in the Territory, less the following deductions [***],
determined in accordance with [***]: [***]. 
 If a Product is sold under an installment payment plan or other payment plan under which the
sales price is invoiced in increments over time, Net Sales will be recognized as installments or increments are [***]. 
 In no event shall
any particular amount identified above be deducted more than once in calculating Net Sales (i.e., no “double counting” of deductions). 

Sales of Products between or among the Selling Parties for resale by a Selling Party shall not be included in the calculation of Net Sales;
provided that the subsequent sale, if any, shall be included in the calculation of Net Sales. Products provided to Third Parties [***] for use in Clinical Trials shall not be included in the calculation of Net Sales. 

1.45 “Option Field” means, with respect to each Option Promoter, the cure, treatment, palliation, prevention or diagnosis of
those indications set forth on Exhibit A. 
 1.46 “Option Promoter” means a Synthetic Promoter that (a) is designed,
built and tested or otherwise identified by Senti under the Research Program, (b) is intended to have one of the Promoter Profiles and (c) is selected by Spark in accordance with Section 3.8.3. 

1.47 “Out-of-Pocket Costs” means, with respect
to Senti’s activities conducted under the Research Plan, expenses actually paid by Senti to Third Parties to conduct such activities, but excluding any costs included in the FTE Rate. 

1.48 “Party” means Senti or Spark, as the context requires. 

1.49 “Parties” means Senti and Spark. 

1.50 “Patent Challenge” means any administrative or legal procedure or action before an agency (including the United States
Patent and Trademark Office) or filed in a court attempting to challenge or oppose the validity or enforceability of a Patent Right or claims thereof in the Territory, or to have a Patent Right or claims thereof declared or adjudicated invalid,
unenforceable or unpatentable in the Territory. For the avoidance of doubt, a Patent Challenge includes post-grant reviews ̧ ex parte examinations and inter partes reviews in the United States Patent and Trademark Office seeking
review or reexamination of any Patent Right or claim thereof. 

  
 - 7 - 

 1.51 “Patent Right” means any patent (including any certificate of
correction, substitution, extension (including any patent term extension), registration, confirmation, reissue, re-examination or renewal) or patent application (including any provisional application, utility
application, divisional, continuation or continuation-in-part). 

1.52 “Person” means any natural person, corporation, general partnership, limited partnership, joint venture, proprietorship
or other business organization or a Governmental Authority. 
 1.53 “Phase I Clinical Trial” means a Clinical Trial that
would satisfy the requirements of 21 C.F.R. § 312.21(a), or its foreign equivalent. 
 1.54 “Phase I/II Clinical Trial”
means a Clinical Trial that would satisfy the requirements of (a) 21 C.F.R. § 312.21(a) and 21 C.F.R. § 312.21(b), or their foreign equivalents or (b) 21 C.F.R. § 312.21(b), or its foreign equivalent. 

1.55 “Phase II Clinical Trial” means a Clinical Trial that would satisfy the requirements of 21 C.F.R. § 312.21(b), or
its foreign equivalent. 
 1.56 “Phase III Clinical Trial” means a Clinical Trial that would satisfy requirements of 21
C.F.R. § 312.21(c), or its foreign equivalent. 
 1.57 “Pivotal Clinical Trial” means a Clinical Trial that [***]. 

1.58 “Product” means, with respect to a particular Licensed Promoter, an in vivo gene therapy product incorporating
such Licensed Promoter[***]. 
 1.59 “Promoter Profile” means one of the five (5) promoter profiles set forth in
Exhibit B. 
 1.60 “Prosecution and Maintenance” means, with respect to a Patent Right, the preparing, filing, prosecuting
and maintenance of such Patent Right, as well as re-examinations and reissues, with respect to such Patent Right, together with the conduct of interferences, the defense of oppositions and other similar
post-grant proceedings with respect to the particular Patent Right. “Prosecute and Maintain” shall have the correlative meaning. 

1.61 “Publication” means any publication in a scientific journal, any public presentation of a scientific abstract, any
presentation at any scientific conference (including slides and texts of oral or other public presentations), any other public scientific presentation and any other oral, written or electronic scientific disclosure directed to a public audience
that, in each case, pertains to an Option Promoter, Licensed Promoter, Product or the use of any of the foregoing. 
 1.62
“Regulatory Approval” means all approvals, licenses, registrations and authorizations by a Regulatory Authority that are necessary for the marketing and sale of a pharmaceutical product in a country or group of countries (including
commercially or legally necessary price and reimbursement approvals), including approved BLAs and MAAs and any approved supplemental applications therefor. 

  
 - 8 - 

 1.63 “Regulatory Authority” means any Governmental Authority with authority
over the marketing, pricing or sale of a pharmaceutical product in a country, including the FDA and the EMA. 
 1.64 “Regulatory
Materials” means regulatory applications, submissions, notifications, registrations, marketing authorizations (including Regulatory Approvals), or other written materials, correspondence, or submissions made to or with a Regulatory
Authority that are necessary or reasonably desirable in order to Develop, Manufacture or Commercialize a product in a particular country. 

1.65 “Representative” means, with respect to a Person, any director, officer or employee of such Person, or any Third Party
consultant, subcontractor, attorney, accountant, agent or advisor of such Person. 
 1.66 “Research Term” means the period
commencing on the Effective Date and expiring [***] thereafter; provided, however, that [***]. 
 1.67
“Results” means results, data [***], conclusions and findings generated or obtained by or on behalf of Senti or Spark (or, if applicable, the Parties jointly) in the performance of activities under the Research Program. 

1.68 “Royalty Term” means, on a
Product-by-Product and country-by-country basis, the period of time commencing on the
date of First Commercial Sale of such Product in such country and continuing until the last-to-occur of the following: (a) expiration of the last Valid Claim of a
Senti Patent Right Covering [***] in such country; (b) termination or expiration of regulatory or data exclusivity for such Product in such country; and (c) [***] years from the First Commercial Sale of such Product in such country. 

1.69 “Senti Know-How” means, subject to Section 5.5.2, any Know-How that is (a) Controlled by Senti or any of its Affiliates as of the Effective Date or any time during the Term and (b) [***] to Develop, Manufacture, Commercialize or otherwise exploit the applicable
Licensed Promoter (including as part of a Product), [***]. 
 1.70 “Senti Materials” means all biological materials
(a) that are generated under or resulting from activities under the Research Program with respect to an Option Promoter that is intended to have a given Promoter Profile, (b) that are Controlled by Senti or its Affiliates, and
(c) which Senti transfers or delivers to Spark for the conduct of the Evaluation Program for such Promoter Profile. 
 1.71
“Senti Patent Rights” means, subject to Section 5.5.2, any Patent Rights that are (a) Controlled by Senti or any of its Affiliates as of the Effective Date or at any time during the Term, and any
Counterparts thereof and (b) [***] to Develop, Manufacture, Commercialize or otherwise exploit the applicable Licensed Promoter (including as part of a Product), including Senti’s interest in any Joint Patent Rights [***]. 

  
 - 9 - 

 1.72 “Senti Platform” means Patent Rights and Know-How that are [***] and are [***]. For clarity, the Senti Platform [***]. 
 1.73 “Senti
Technology” means the Senti Know-How and the Senti Patent Rights. 
 1.74 “Spark Know-How” means any Know-How that is (a) Controlled by Spark or any of its Affiliates as of the Effective Date or any time during the Research Term and (b) [***]
to conduct the Research Program. 
 1.75 “Spark Materials” means cell lines or any other biological materials that are
Controlled by Spark or its Affiliates, and which Spark transfers or delivers to Senti for use in the Research Program. 
 1.76 “Spark
Patent Rights” means all Patent Rights that are (a) Controlled by Spark or any of its Affiliates as of the Effective Date or at any time during the Research Term, and any Counterparts thereof and (b) [***] to conduct the Research
Program. 
 1.77 “Spark Technology” means the Spark Know-How and the Spark Patent
Rights. 
 1.78 “Sublicensee” means a Third Party to whom Spark or one of its Affiliates or another Sublicensee has granted
a license or sublicense in accordance with Section 5.4. For the avoidance of doubt, “Sublicensee” shall [***]. 

1.79 “Synthetic Promoter” means a [***] that, with respect to a cell type, is [***] in such cell type [***]. 

1.80 “Territory” means any country of the world. 

1.81 “Third Party” means any Person other than Senti or Spark or any of their respective Affiliates. 

1.82 “United States,” “US” or “U.S.” means the United States of America and its territories
and possessions. 
 1.83 “Valid Claim” means a claim of (a) an issued and unexpired Patent Right that has not
(i) irretrievably lapsed or been revoked, dedicated to the public or disclaimed or (ii) been held invalid, unenforceable or not patentable by a court, governmental agency, national or regional patent office or other appropriate body that
has competent jurisdiction, which holding, finding or decision is final and unappealable or unappealed within the time allowed for appeal, or (b) a pending application for a Patent Right that [***] and has not been abandoned or finally
disallowed without the possibility of appeal, provided that if such a pending patent application [***]. 
 1.84
“Vendor” means a Third Party engaged by Spark or any of its Affiliates to perform Development, Manufacturing or Commercialization activities with respect to a particular Licensed Promoter or Products incorporating such Licensed
Promoter, including a clinical research organization, contract manufacturing organization, distributor, subcontractor, consultant or other service provider; provided that, such Third Party is not [***]. 

  
 - 10 - 

 1.85 Additional Definitions. Each of the following definitions is set forth in the
section of this Agreement indicated below: 
  

			
	 DEFINITION:
	  	SECTION:
	[***]	  	Section [***]
	Agreement	  	Preamble
	Alliance Manager	  	Section 2.5
	Arbitrator	  	Section 12.3.3(b)
	Bankruptcy Code	  	Section 5.6
	[***]	  	Section [***]
	Collaboration	  	Recitals
	[***]	  	Section [***]
	Competitive Infringement	  	Section 8.4.1

  
 - 11 - 

			
	 DEFINITION:
	  	SECTION:
	Courts	  	Section 13.1
	[***]	  	Section [***]
	Data Package	  	Section 4.1.1
	Data Package Delivery Date	  	Section 10.3
	Disclosing Party	  	Section 1.12
	Dispute Notice	  	Section 4.1.1
	Effective Date	  	Preamble
	Evaluation Period	  	Section 4.1.3
	Evaluation Program	  	Section 2.1.2
	FDCA	  	Section 1.3
	Force Majeure	  	Section 14.8
	FTE	  	Section 1.28
	FTE Costs	  	Section 7.2.2
	ICH	  	Section 1.29
	Infringement	  	Section 8.4.1
	Infringement Claim	  	Section 8.3
	Joint Patent Rights	  	Section 8.2.1
	Joint Patent Working Group	  	Section 2.4
	JPT	  	Section 2.3.1
	JRC	  	Section 2.2.1(a)
	Materials Transfer Letter	  	Section 3.6.1
	Non-Publishing Party	  	Section 9.4.5
	Notice of Dispute	  	Section 13.2.1
	Notice Period	  	Section 12.2.1
	Option Exercise Notice	  	Section 4.2.2
	Option Promoter Selection Period	  	Section 3.8.3
	Parent	  	Section 1.2
	Promoter Change	  	Section 8.1.2(b)(ii)
	Promoter Improvement	  	Section 8.1.2(b)(i)
	Publishing Party	  	Section 9.4.5
	Receiving Party	  	Section 1.12
	Redacted Version	  	Section 9.6.2
	Research Budget	  	Section 7.2.1
	Research Plan	  	Section 3.2
	Research Program	  	Section 2.1.1
	Reversion License	  	Section 12.3.1(c)
	Selling Party	  	Section 1.45
	Senti	  	Preamble
	Senti Indemnitees	  	Section 11.1
	Senti Platform Improvements	  	Section 8.1.2(a)
	Senti Responsibility Patents	  	Section 8.2.3
	Senti Third Party Agreement	  	Section 5.5.2
	Skipped Milestone	  	Section 7.4.2
	Spark	  	Preamble
	Spark Indemnitees	  	Section 11.2

  
 - 12 - 

			
	 DEFINITION:
	  	SECTION:
	Spark Option	  	Section 4.2.1
	Spark Responsibility Patents	  	Section 8.2.2
	[***]	  	Section [***]
	[***]	  	Section [***]
	Subsidiary	  	Section 1.2
	Term	  	Section 12.1
	[***]	  	Section [***]

 ARTICLE 2 

OVERVIEW AND GOVERNANCE 

2.1 Overview of Research Collaboration. The Parties intend and have agreed to undertake the Collaboration under this Agreement
consisting of the following components: 
 2.1.1 a research program pursuant to which Senti will design, build, and test Synthetic Promoters
that are intended to have a given Promoter Profile during the Research Term in accordance with Section 3.2 (the “Research Program”); and 

2.1.2 with respect to each Promoter Profile, an evaluation program to evaluate Option Promoters for such Promoter Profile in the applicable
Option Field, to be conducted by Spark in accordance with Section 4.1 (each, an “Evaluation Program”). 

2.2 Joint Research Committee. 

2.2.1 Formation; Composition and Meetings. 

(a) The Parties will establish a joint research committee (the “JRC”), consisting of [***] members total, with [***] named
representatives of each of Spark and Senti, within [***] after the Effective Date. Each Party will provide the other Party in writing with the name, title, e-mail address, and telephone number of their initial
JRC members. 
 (b) The JRC will meet as frequently as both Parties agree is appropriate, but not less than [***], and more often as
necessary. Such meetings will be at such times as are agreed to by Spark and Senti, and will alternate between the offices of the Parties, unless the Parties otherwise agree, or will be in such other form (e.g., telephone conference call, internet
meetings or videoconference) as the members of the JRC may agree. Each Party will be responsible for all costs incurred by it relating to such meetings. 

(c) Each Party shall be free to change its representatives on notice to the other Party or to send a substitute representative to the JRC
meeting; provided that each Party shall ensure that, at all times during the existence of the JRC, its representatives on the JRC are appropriate in terms of expertise and seniority for the then-current stage of the Research Program or
development of the Option Promoters and have the authority to bind such Party with respect to matters within the purview of the JRC. Each Party’s representatives and any substitute for a representative shall be bound by the obligations of
confidentiality set forth in Article 9. 

  
 - 13 - 

 2.2.2 JRC Functions and Powers. The JRC will be responsible for the overall oversight
of the Research Program and activities thereunder with respect to Option Promoters that are intended to have a given Promoter Profile until, on a Promoter
Profile-by-Promoter Profile basis, [***] for such Promoter Profile, and thereafter the JRC shall serve as a forum for sharing of information of the Parties with respect
to [***] for such Promoter Profile. The principal functions of the JRC will be: 
 (a) overseeing and monitoring the progress and results of
the Research Program, [***]; 
 (b) approving amendments to the Research Plan recommended by the JPT; 

(c) creating new subcommittees or working groups as necessary; 

(d) fostering the collaborative relationship between the Parties; 

(e) resolving disputes at the JPT or any other subcommittee; 

(f) disclosure or sharing of information relating to the Synthetic Promoters being designed, built and tested under the Research Plan; 

(g) on a Promoter Profile-by-Promoter Profile basis, meeting
and reviewing [***]; 
 (h) during [***] for a Promoter Profile, reviewing and discussing [***] such Promoter Profile; and 

(i) such other functions as agreed by the Parties. 

2.2.3 Subcommittees. The JRC may establish and disband subcommittees as deemed necessary by the JRC. Each such subcommittee shall
consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on notice to the other or to send a substitute representative to any
subcommittee meeting; provided that each Party shall ensure that, at all times during the existence of any subcommittee, its representatives on such subcommittee are appropriate in terms of expertise and seniority for the then-current stage
of the Research Program or development of the Option Promoters and have the authority to bind such Party with respect to matters within the purview of the relevant subcommittee. Each Party’s representatives and any substitute for a
representative shall be bound by the obligations of confidentiality set forth in Article 9. Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall
report to, and have any disputes in such committee resolved by, the JRC. 2.2.4 Decisions. (a) Except as otherwise provided herein, all decisions of the JRC shall be made unanimously, with each Party’s representatives on the JRC
collectively having one vote. If the JRC is unable to reach a unanimous decision within [***] after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue referred to the Executive
Officers of each Party for resolution. The Executive Officers shall promptly discuss the issue submitted and seek to determine a resolution. If the Executive Officers are unable to determine a resolution within [***] after the issue was referred to
them, then Spark shall have the authority to make the final decision with respect to [***]. 

  
 - 14 - 

 (b) The JRC shall not have authority to amend, modify or waive compliance with the terms
and conditions of this Agreement, or to interpret, alter, increase, expand, or waive a Party’s rights or obligations under this Agreement. Notwithstanding anything contained in this Agreement to the contrary, it is expressly understood and
agreed that in no event shall Spark exercise its final decision-making authority to (i) [***] set forth in the Research Plan, (ii) [***] set forth in the Research Plan, [***] in accordance with the terms of this Agreement, (iii) [***] set forth in
the Research Plan, (iv) [***] pursuant to the Research Plan, (v) [***] to the Research Program, or (vi) alter the Research Plan in a manner that would be reasonably expected to cause Senti to violate applicable Law, in each case ((i), (ii),
(iii), (iv), (v) or (vi)), without the prior written consent of Senti. For clarity, any changes to [***] shall be deemed to [***] set forth in the Research Plan. 

(c) Notwithstanding any other provision of this Agreement, upon the conclusion of [***], the JRC shall cease to have any decision-making
authority and shall serve only as a forum for discussion and information exchange regarding [***]. 
 2.2.5 Dissolution. Upon [***],
unless the Parties conclude and mutually agree in writing that [***] merits retention of the JRC, the JRC will be dissolved. 
 2.3 Joint
Project Team. 
 2.3.1 Formation; Composition and Meetings. Within [***] after the Effective Date, the Parties shall establish a
joint project team (the “JPT”) as more fully described in this Section 2.3. The JPT shall be comprised of an equal number of representatives from each of Spark and Senti with the appropriate scientific
expertise with respect to the conduct of the Research Plan and shall meet [***] (or more or less frequently as agreed by the Parties) during the Research Term. Such meetings will be at such times as are agreed to by Spark and Senti and will
alternate between the offices of the Parties, unless the Parties otherwise agree, or will be in such other form (e.g., telephone conference call, internet meetings or videoconference) as the members of the JPT may agree. Each Party will bear all
expenses it incurs in regard to participating in all meetings of the JPT, including all travel and living expenses. 
 2.3.2 JPT Functions
and Powers. The JPT will report to the JRC and will be responsible for the day-to-day management of the conduct of the Research Plan, including: 

(a) overseeing, reviewing and coordinating the conduct of activities under the Research Plan and tracking the activities against the Research
Plan and the Research Budget; 
 (b) overseeing the conduct of experiments and reviewing data resulting from such experiments as set forth
in the Research Plan; 
 (c) reviewing, commenting on and [***] amending the Research Plan, subject to approval by the JRC; 

  
 - 15 - 

 (d) exchanging information regarding the Option Promoters and other Synthetic Promoters
being designed, built and tested under the Research Plan; and 
 (e) reviewing and making determinations with respect to transfers of Know-How and Senti Materials, including to [***]. 
 2.3.3 Decisions. All decisions of the JPT on
matters for which it has responsibility shall be made unanimously, with each Party’s representatives on the JPT collectively having one vote. In the event that the JPT is unable to reach a unanimous decision within [***] after it has met and
attempted to reach such decision, then either Party may, by written notice to the other Party, have such issue submitted to the JRC for resolution in accordance with Section 2.2.4. 

2.3.4 Dissolution. Upon the conclusion of the Research Term, the JPT will be dissolved. 

2.4 Joint Patent Working Group. The Parties will establish a joint patent working group (the “Joint Patent Working
Group”), consisting of at least [***] from each Party or any other number of experts as the JRC may agree upon (with an equal number of experts from each of Senti and Spark), within [***] after the Effective Date. The Joint Patent Working
Group will be responsible for the coordination of the Parties’ efforts in respect of managing the preparation, filing, prosecution, maintenance, enforcement and defense of the Senti Patent Rights in accordance with the provisions set forth in
Article 8. 
 2.5 Alliance Managers. Each Party will appoint an individual designated as the alliance manager (each, an
“Alliance Manager”). The Alliance Managers will be the main point of contact for each Party to exchange information, facilitate communication and coordinate the Parties’ activities under the Collaboration and to provide support
to the JRC, JPT and any other subcommittees. 
 2.6 Co-Chairs. The JRC, JPT and each
subcommittee shall have co-chairpersons. Spark and Senti shall each select a co-chairperson for the JRC, JPT and each subcommittee, and each Party may change its
designated co-chairperson from time to time upon written notice to the other Party. The co-chairpersons of the JRC, JPT and each subcommittee, with assistance and
guidance from the Alliance Managers, shall be responsible for calling meetings and preparing and circulating an agenda in advance of each meeting of the JRC, JPT and each subcommittee; provided that the JRC, JPT and each
subcommittee co-chairpersons shall call a meeting of the JRC, JPT or applicable subcommittee promptly upon the written request of either co-chairperson to convene such a
meeting. 
 2.7 Minutes and Reports. The Alliance Managers will be responsible for keeping accurate minutes of the JRC or JPT (or, if
applicable, any subcommittee) deliberations that record all proposed decisions and all actions recommended or taken. Within [***] of each meeting, the Alliance Managers will provide the JRC or JPT (or, if applicable, any subcommittee) with draft
minutes of such meeting. Minutes will be deemed approved unless either Party’s representative objects to the accuracy of such minutes or accompanying report by providing notice to the other Party’s representative within [***] of receipt of
such minutes and report. In the event that any such objection is not resolved by the JRC, JPT or applicable subcommittee, such minutes and accompanying report will be amended to reflect such unresolved dispute. Subject to the terms and conditions of
this Agreement, all records of the JRC, JPT and each subcommittee will be considered Confidential Information of, and be available to, both Parties. 

  
 - 16 - 

 2.8 Information and Results. Except as otherwise provided in this Agreement, the
Parties will make available and disclose to one another [***] prior to and in preparation for the JRC, JPT or applicable subcommittee meetings, [***] to be designated by the JRC, JPT or applicable subcommittee; provided, that (a) [***] and
(b) [***]. 
 ARTICLE 3 

RESEARCH PROGRAM 
 3.1
Overview. The Parties shall conduct the Research Program during the Research Term in accordance with the terms and conditions set forth in this Agreement and the Research Plan. Senti will be the lead party for conducting the Research Program.

 3.2 Research Plan. All activities to be conducted under the Research Program shall be set forth in a written plan (such plan, as
amended from time to time, the “Research Plan”), which Research Plan shall include (a) the Promoter Profiles, (b) the research activities to be undertaken by Senti [***] and anticipated timelines for such activities,
(c) the Spark Materials, if any, to be provided by Spark for use by Senti in the Research Program, (d) the Senti Materials to be provided by Senti to Spark for the conduct of the Evaluation Program, and (e) the budget (based on FTEs
and Out-of-Pocket Costs) for Senti’s activities under the Research Program. The initial Research Plan is attached hereto as Exhibit C. During the Research Term,
either Party may propose amendments to the Research Plan in writing to the JPT, which shall become effective upon approval by the JRC in accordance with Section 2.3; provided, that, unless otherwise agreed by the
Parties, [***] after JRC approval. 
 3.3 Recordkeeping. Senti shall maintain customary written (or electronic) records for the work
performed by Senti under the Research Program in good scientific order and sufficient for patent and regulatory purposes. Upon the completion of activities under the Research Plan, Senti shall prepare a final written report to summarize the work
performed and the Results generated by Senti from the Research Program, which report shall be [***], and deliver such report to the JRC to review. 

3.4 Subcontracts. Subject to the terms and conditions of this Agreement, Senti may subcontract to Affiliates and Third Parties
(including contract research organizations) any activities to be performed under the Research Plan; provided, however, that (a) with respect to any such Affiliate subcontractor, Senti shall be required to (i) [***] and
(ii) enter into or already have in place appropriate agreements with such Affiliate with respect to non-disclosure of Confidential Information and ownership of any intellectual property developed in the
course of subcontracted activities, in each case, consistent with the terms of this Agreement, and (b) with respect to any Third Party subcontractor, Senti shall be required to (i) [***] and (ii) enter into or already have in place
appropriate agreements with such permitted Third Party subcontractor respect to non-disclosure of Confidential Information and ownership of any intellectual property developed in the course of subcontracted
activities, in each case, consistent with the terms of this Agreement. Senti will also enter into quality agreements with such Affiliates and approved Third Parties as required, in each case, on customary terms consistent with this Agreement. Senti
shall remain liable to Spark for any act or omission of its Affiliates or Third Party subcontractors and any and all failures by such Affiliates or Third Party subcontractors to comply with the terms of this Agreement. 

  
 - 17 - 

 3.5 Performance; Funding. Each Party shall perform all activities assigned to
it under the Research Plan in accordance with the terms thereof and of this Agreement. For each Promoter Profile, Senti shall use Commercially Reasonable Efforts to generate and provide to Spark [***] Synthetic Promoters for such Promoter Profile in
accordance with the Research Plan and the timelines set forth therein. Senti will perform, at its own cost and expense (subject to reimbursement by Spark of the Research Program costs in accordance with Section 7.2), any
activities for which it is responsible under the Research Plan. Spark will perform, at its own cost and expense, any activities for which it is responsible under the Research Plan. 

3.6 Provision of, Use and Return of Spark Materials. 

3.6.1 Provision of Spark Materials. Any Spark Materials provided to Senti shall be accompanied by a materials transfer letter
substantially in the form of Exhibit E (a “Materials Transfer Letter”). Each such Materials Transfer Letter shall be signed by a representative of Spark and a representative of Senti. WITHOUT LIMITING THE TERMS OF THE
MATERIALS TRANSFER LETTER, SENTI ACKNOWLEDGES THAT THE SPARK MATERIALS ARE BEING SUPPLIED WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE SPARK MATERIALS
WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. SENTI ACKNOWLEDGES AND ACCEPTS THAT THE SPARK MATERIALS ARE EXPERIMENTAL IN NATURE, MAY HAVE UNKNOWN CHARACTERISTICS, MAY CARRY INFECTIOUS AGENTS, OR MAY BE OTHERWISE HAZARDOUS.
SENTI AGREES TO USE CAUTION AND PRUDENCE IN THE HANDLING, STORAGE, TRANSPORTATION, CONTAINMENT AND USE OF THE SPARK MATERIALS. 
 3.6.2
Use and Return of Spark Materials. Senti shall only use the Spark Materials to conduct the Research Program in accordance with the Research Plan during the Research Term. Senti shall not use Spark Materials for any other purposes. Senti shall
not transfer the Spark Materials to any Third Party unless set forth in the Research Plan or otherwise approved in writing by Spark. Spark retains all right, title and interest in and to the Spark Materials. Senti shall not use any such Spark
Materials provided by Spark in humans or for any commercial purposes. Senti shall not attempt to reverse engineer, deconstruct, design around or in any way determine the structure, sequence or composition of any such Spark Materials or, except as
specified in the Research Plan, generate analogs, derivatives or formulations based on any such Spark Materials or chemically analyze or chemically modify the structure of any such Spark Materials. Within [***] after the end of the Research Term,
Senti shall return to Spark, or destroy and certify destruction of, any remaining Spark Materials. 
 3.7 [***]. 

3.7.1 [***]. 
 3.7.2 [***]. 

  
 - 18 - 

 3.7.3 [***]. 

3.8 Results Reporting; [***] and Selection of Option Promoters. 

3.8.1 Senti shall disclose to and review with Spark at each JPT meeting [***] under the Research Program, including by providing [***] written
reports to the JPT summarizing the work performed by Senti [***], which reports will include [***]; provided, that Senti may [***]. 

3.8.2 At Spark’s reasonable request at any time and from time to time during the Research Term (including in connection with Spark’s
selection of Option Promoters in accordance with Section 3.8.3), on a Promoter Profile-by-Promoter Profile basis, Senti shall disclose to Spark
[***] for such Promoter Profile at such time; provided, however, that Senti shall [***]. Spark shall use [***] in its performance of the Research Plan. Except to the extent contemplated by this
Section 3.8.2, Senti shall [***]. 
 3.8.3 On a Promoter Profile-by-Promoter Profile basis, within [***] following the completion of Senti’s work under the Research Plan that has the goal of generating Synthetic Promoters that meet such Promoter Profile, the
JRC shall meet and review all of the final Synthetic Promoters resulting from such work. Spark shall have a period of [***] (the “Option Promoter Selection Period”) following such meeting to review such final Synthetic Promoters and
any corresponding data in order to evaluate such Synthetic Promoters for potential selection by Spark as Option Promoters. Senti shall cooperate with Spark in connection with such evaluation process, including, to the extent requested by Spark
within [***] following such initial JRC meeting, [***] to further discuss such Synthetic Promoters and any questions that Spark may have with respect thereto. At any time prior to expiration of the Option Promoter Selection Period, Spark may provide
written notice to Senti of those final Synthetic Promoters that it wishes to select as “Option Promoters”; provided, however, that Spark shall [***] for such Promoter Profile. 

ARTICLE 4 
 EVALUATION
PROGRAM; OPTION RIGHTS 
 4.1 Evaluation Program. 

4.1.1 With respect to each Promoter Profile, promptly following Spark’s selection in accordance with
Section 3.8.3 of Option Promoters with respect to a particular Promoter Profile, Senti shall provide a data package to Spark, which data package will be in the form of the template data package attached as Exhibit G
and include: [***] (each, a “Data Package”). In addition, together with delivery of the Data Package, Senti shall deliver all Senti Materials for such Option Promoters that are specified in the Research Plan. The Parties may modify
the required contents of the Data Package or the Senti Materials to be provided to Spark by means of an amendment to the Research Plan approved in accordance with Section 3.2. If Spark believes in good faith that a
Data Package or Senti Materials are incomplete, it shall notify Senti within [***] following Spark’s receipt of such Data Package or Senti Materials. If Senti disagrees, it shall provide written notice to Spark thereof (“Dispute
Notice”) within [***] following Senti’s receipt of such notice, and such dispute shall be escalated to the Executive Officers, who will attempt to resolve such dispute within [***] following Spark’s receipt of the Dispute Notice.
If the Executive Officers do not resolve such dispute [***] after such dispute is escalated to the Executive Officers, either Party may submit such dispute to an independent Third Party expert agreed upon by the Parties who shall resolve such
dispute no later than [***] thereafter. If the Executive Officers or the Third Party expert determine(s) that (i) the initial Data Package or Senti Materials are incomplete, the Evaluation Period shall [***], or (ii) the initial Data
Package and Senti Materials are complete, the Evaluation Period shall [***] the costs of such independent Third Party expert. 

  
 - 19 - 

 4.1.2 Senti shall, during the Evaluation Period for such Promoter Profile, as reasonably
requested by Spark, meet with Spark to discuss the Data Package and Senti Materials and any questions that Spark may have with respect thereto, and provide Spark with such additional information in Senti’s possession and Control (without any
requirement to conduct further activities) as reasonably requested by Spark to assist with its interpretation of the Data Package, evaluation of the Senti Materials, conduct of activities under the Evaluation Program and determination as to whether
to exercise the Spark Option with respect to an Option Promoter. [***]. 
 4.1.3 On a Promoter Profile-by-Promoter Profile basis, during the period (a) commencing on [***] and (b) expiring [***] (such period, the “Evaluation Period”), Spark shall have the right to perform, at
its sole expense, [***] to evaluate such Option Promoters and determine its interest in exercising the Spark Option with respect to any such Option Promoter. During the applicable Evaluation Period, Spark shall keep the JRC reasonably informed of
its progress with respect to the Evaluation Program, and provide the JRC [***] under the applicable Evaluation Program (including[***]), during such period. In addition, Spark shall provide the JRC a final report within [***] following the [***]
from such Evaluation Program. For clarity, during the applicable Evaluation Period, Spark shall not have the right to (A) [***], or (B) conduct any [***] clinical Development or Commercialization activities under the Evaluation Program with
respect to the applicable Option Promoter(s). 
 4.1.4 Subject to the terms and conditions of this Agreement, Spark may subcontract to
Affiliates and Third Parties (including contract research organizations) any activities to be performed under the Evaluation Program in accordance with Section 4.1.3 [***]; provided that (a) the transfer of any
Senti Materials by Spark to any such Third Party subcontractor shall be [***], and (b) Spark shall be required to enter into or already have in place appropriate agreements with such Affiliate or Third Party with respect to non-disclosure of Confidential Information and ownership of any intellectual property developed in the course of subcontracted activities, in each case, consistent with the terms of this Agreement. Spark shall
remain responsible and liable for acts and omissions of its Affiliates or Third Party subcontractors hereunder and any and all failures by such Affiliates or Third Party subcontractors to comply with the terms of this Agreement. 

4.2 Spark Option. 
 4.2.1
Spark Option Grant. Senti hereby grants to Spark the exclusive right, exercisable at Spark’s sole discretion, on a Promoter Profile-by-Promoter Profile basis
in accordance with Section 4.2.2, to be granted the license under Section 5.1.2 with respect to any Option Promoter for such Promoter Profile (each such right, a “Spark Option”).

  
 - 20 - 

 4.2.2 Spark Option Exercise. Spark, on its own behalf or on behalf of any of
its Affiliates, may exercise a Spark Option with respect to an Option Promoter and Products incorporating such Option Promoter by delivery to Senti of written notice of exercise at any time prior to the end of the applicable Evaluation Period for
such Option Promoter. The written notice of exercise (the “Option Exercise Notice”) shall identify (a) the applicable Promoter Profile and Option Promoter, (b) [***], (c) [***], and (d) [***]. Upon exercise of a Spark Option,
Spark shall pay the applicable licensing fee in accordance with Section 7.3. 
 4.2.3 Non-Exercise of Spark Option. If Spark (a) does not exercise a Spark Option with respect to any Option Promoters for a given Promoter Profile in accordance with
Section 4.2.2 during the applicable Evaluation Period for such Promoter Profile, or (b) notifies Senti in writing prior to the expiration of such Evaluation Period that Spark will not exercise such Spark Option, then
(i) such Spark Option shall immediately expire without any further action required on the part of either Party, (ii) Spark shall not have any rights with respect to such Option Promoters and (iii) Senti may Develop, Manufacture,
Commercialize and otherwise exploit products incorporating such Option Promoters, whether directly or with or through Affiliates or Third Parties, without any obligation to Spark. 

4.3 Provision of, Use and Return of Senti Materials. 

4.3.1 Provision of Senti Materials. Any Senti Materials provided to Spark shall be accompanied by a Materials Transfer Letter. Each such
Materials Transfer Letter shall be signed by a representative of Spark and a representative of Senti. WITHOUT LIMITING THE TERMS OF THE MATERIALS TRANSFER LETTER, SPARK ACKNOWLEDGES THAT THE SENTI MATERIALS ARE BEING SUPPLIED WITH NO
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE SENTI MATERIALS WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY. SPARK ACKNOWLEDGES AND
ACCEPTS THAT THE SENTI MATERIALS ARE EXPERIMENTAL IN NATURE, MAY HAVE UNKNOWN CHARACTERISTICS, MAY CARRY INFECTIOUS AGENTS, OR MAY BE OTHERWISE HAZARDOUS. SPARK AGREES TO USE CAUTION AND PRUDENCE IN THE HANDLING, STORAGE, TRANSPORTATION, CONTAINMENT
AND USE OF THE SENTI MATERIALS. 
 4.3.2 Use and Return of Senti Materials. Spark and its Affiliates shall only use the Senti
Materials (a) to conduct the Evaluation Program with respect to a given Promoter Profile during the applicable Evaluation Period to assess whether to exercise a Spark Option for any Option Promoter with respect to such Promoter Profile during
the Evaluation Period or (b) upon exercise of the Spark Option with respect to such Option Promoter, pursuant to the license granted under Section 5.1.2 while such license is in effect; provided that, in each
case of (a) and (b), Spark shall not transfer the Senti Materials to any Third Party other than a Third Party subcontractor permitted under Section 4.1.4 unless set forth in the Research Plan or otherwise approved in
writing by Senti. Spark and its Affiliates shall not use Senti Materials for any other purposes. Senti retains all right, title and interest in and to the Senti Materials. Spark shall not use any such Senti Materials provided by Senti in humans or
for any commercial purposes. Spark shall not attempt to reverse engineer, deconstruct, design around or in any way determine the structure, sequence or composition of any such Senti Materials, and except as specified in the Research Plan, generate
analogs, derivatives or formulations based on any such Senti Materials, or chemically analyze or chemically modify the structure of any such Senti Materials. If Spark does not exercise a Spark Option with respect to any Option Promoter that is
intended to have a given Promoter Profile, Spark shall return to Senti or destroy and certify the destruction of any unused Senti Materials with respect to all Option Promoters that are intended to have such Promoter Profile, as applicable. 

  
 - 21 - 

 ARTICLE 5 

LICENSE GRANTS 
 5.1
License Grants to Spark. 
 5.1.1 Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Senti
hereby grants to Spark, on a Promoter Profile-by-Promoter Profile basis, during the applicable Evaluation Period for such Promoter Profile, an exclusive, non-transferrable (except in accordance with Section 14.6), sublicensable (solely in connection with any activities subcontracted pursuant to Section 4.1.4),
worldwide, fully paid-up, and royalty-free license (or sublicense, as applicable), under the Senti Technology, solely for Spark to conduct its activities under such Evaluation Program; and 

5.1.2 Subject to the terms and conditions of this Agreement, effective as of the date of Spark’s delivery of the applicable Option
Exercise Notice, Senti hereby grants to Spark (or any Affiliate(s) for which Spark exercised the applicable Spark Option), on a Licensed Promoter-by-Licensed Promoter
basis, an exclusive (even as to Senti), non-transferrable (except in accordance with Section 14.6), sublicensable (in accordance with Section 5.4),
worldwide, and royalty-bearing license (or sublicense, as applicable), under the Senti Technology, to Develop, Manufacture, Commercialize and otherwise exploit Products incorporating the applicable Licensed Promoter in the applicable Licensed Field
in the Territory. 
 5.2 No Implied Rights; Negative Covenant. Except as expressly provided in this Agreement, neither Party shall be
deemed to have granted to the other Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any intellectual property, Know-How, Patent Rights or other
information owned by or licensed to such Party or its Affiliates. Without limiting the foregoing, Spark shall [***] (a) Affiliates [***] or (b) Sublicensees [***]. Notwithstanding the exclusive license granted by Senti to Spark under
Section 5.1.1, Senti retains the rights under the Senti Technology to perform its obligations under this Agreement, whether directly or through one or more subcontractors pursuant to Section 3.4.
For the avoidance of doubt, Senti retains all rights under the Senti Technology outside the scope of the licenses granted to Spark under Section 5.1, including with respect to Licensed Promoters for use in Products outside
the Licensed Field and for use in products that are not Products. 
 5.3 License Grant to Senti. During the Research Term, Spark
hereby grants to Senti a non-exclusive, non-transferrable (except in accordance with Section 14.6), sublicensable (solely in connection with
any activities subcontracted pursuant to Section 3.4), worldwide, fully paid-up, and royalty-free license (or sublicense, as applicable), under the Spark Technology, solely for Senti
to conduct its activities under the Research Program. 

  
 - 22 - 

 5.4 Sublicensing Rights. Spark shall have the right to grant sublicenses under the
licenses granted to Spark pursuant to Section 5.1 to subcontractors in accordance with Section 4.1.4. In addition, Spark shall have the right to grant sublicenses under the licenses granted to
Spark pursuant to Section 5.1.2 to its Affiliates and to Third Parties (which sublicensed rights may be further sublicensable through multiple tiers). Each sublicense to a Third Party must be granted pursuant to a written
sublicense agreement consistent with the requirements of this Agreement applicable to sublicenses, and Spark shall provide to Senti a reasonably redacted copy of any sublicense agreement entered into by Spark or an Affiliate with a
Sublicensee within [***] after the execution of such sublicense agreement, but such copy shall not be redacted to the extent that it [***]. Spark shall remain responsible and liable for any acts and omissions of its Affiliates or Third Party
sublicensees hereunder and any and all failures by such Affiliates or Sublicensees or subcontractors (including Vendors) to comply with the terms of this Agreement. For clarity, [***]. 

5.5 In-Licensed Technology. 

5.5.1 After the Effective Date, if either Party or any of its Affiliates identifies the need for, or is otherwise offered, a license, covenant
not to sue or similar rights to any Third Party Patent Right or Know-How that such Party or its Affiliates in good faith believes is necessary or useful for the Development, Manufacture or Commercialization of
Licensed Promoters (including as part of a Product) in the Licensed Field, then, prior to initiating discussions with any such Third Party with respect to any such license, covenant or right, such Party shall promptly notify the other Party, and the
Parties shall promptly discuss in good faith and coordinate on obtaining such license, covenant or other right from such Third Party. If Parties mutually agree that such Third Party Patent Right or Know-How is
[***], Spark, itself or through any of its Affiliates, shall have the first right to in-license, covenant for, or otherwise obtain such rights on a worldwide or country-by-country basis, [***]. If Parties mutually agree that such Third Party Patent Right or Know-How is [***], Senti, itself or through any of its Affiliates,
shall have the first right to in-license such rights on a worldwide or country-by-country basis, [***]. If the Parties mutually
agree that such Third Party Patent Right or Know-How is [***], either Party shall have the right to in-license, covenant for, or otherwise obtain rights to any such
Third Party Patent Right or Know-How. For clarity, Senti, itself or through any of its Affiliates, shall have the right to in-license, covenant for, or otherwise obtain
rights to any such Third Party Patent Right or Know-How that is [***] on a worldwide or country-by-country basis, [***]. 

5.5.2 If Senti enters into an agreement with a Third Party after the Effective Date pursuant to which Senti
in-licenses, covenants for, or otherwise acquires Control of Patent Rights or Know-How that, subject to this Section 5.5, would constitute
Senti Technology for purposes of this Agreement, then Senti shall promptly provide Spark with notice and a copy of the applicable license or other agreement with the Third Party (a “Senti Third Party Agreement”); provided
that Senti may redact from such copy [***]. Within [***] following receipt of such notice, Spark shall decide, in its sole discretion, whether or not to accept a sublicense under such Patent Rights or Know-How
as Senti Technology and provide Senti written notice of such decision. If Spark accepts such sublicense, (i) such Patent Rights and Know-How shall constitute Senti Technology licensed to Spark under this
Agreement, subject to Senti’s rights under the applicable Senti Third Party Agreement; (ii) [***]; and (iii) Spark shall be obligated to comply with all applicable obligations under such Senti Third Party Agreement (other than any such
obligations that were redacted in the copy provided to Spark). If Spark does not accept such sublicense (including by failing to respond within such [***] period), (x) such Patent Rights and Know-How shall not
constitute, and shall be specifically excluded from, the Senti Technology and shall not be licensed to Spark under this Agreement; and (y) Spark and its Affiliates shall have no obligations with respect to such Senti Third Party Agreement.
[***] as in effect on the Effective Date. All such payments shall be made promptly by Senti in accordance with the terms of the applicable Senti Third Party Agreement. 

  
 - 23 - 

 5.6 Section 365(n) of the Bankruptcy Code. All licenses granted to Spark pursuant to
Section 5.1 are licenses to “intellectual property” (as defined in Section 101(35A) of title 11 of the United States Code (the “Bankruptcy Code”)). Spark shall retain and may
fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Senti or any of its Affiliates under the Bankruptcy Code or analogous
provisions of applicable Law outside the United States, Spark, as a licensee under Senti’s intellectual property, shall be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all
embodiments of such intellectual property, which, if not already in Spark’s possession, shall be promptly delivered to it upon Spark’s request therefor. Nothing in this Section 5.6 shall be deemed any admission
that this Agreement is an executory contract or that this Agreement or any obligation hereunder is otherwise subject to rejection or disavowal in the bankruptcy, liquidation, reorganization, receivership, assignment for the benefit of creditors,
administration, insolvency or similar proceeding or circumstance of Senti, nor any admission that upon any such proceeding or circumstance involving Senti, or upon any such rejection or disavowal by Senti, Spark (or any Affiliate or Sublicensee
thereof) would lose or not be able to enforce or benefit from any right hereunder (or under any applicable sublicense). 
 ARTICLE 6

 DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION 

6.1 Development, Manufacture and Commercialization of Products. 

6.1.1 Following Spark’s exercise of the Spark Option with respect to a Licensed Promoter pursuant to
Section 4.2.2, as between the Parties, Spark shall have the sole right, in its sole discretion (subject to Section 6.3) to Develop, Manufacture, Commercialize and otherwise exploit Products
incorporating such Licensed Promoter in the applicable Licensed Field in the Territory. For clarity, the selection of such Products will be made by Spark, at its sole discretion. Spark or its Affiliates or Sublicensees shall bear all of the costs
and expenses incurred in connection with such Development, Manufacturing, Commercialization and other exploitation activities. 
 6.1.2 Spark
shall provide Senti with [***] Development report [***] Development activities conducted [***] and expected to be conducted [***]. 
 6.2
Regulatory Activities. 
 6.2.1 Without limiting the foregoing Section 6.1, Spark shall have the sole right to
prepare and file all INDs, BLAs, MAAs and other Regulatory Materials for the Products and otherwise to obtain and maintain Regulatory Approvals from Regulatory Authorities that are necessary for the Development, Manufacture, Commercialization and
other exploitation of the Products in the applicable Licensed Field in the Territory. Spark shall have the sole right to interact with Regulatory Authorities as appropriate with respect to the Products in the applicable Licensed Field. 

  
 - 24 - 

 6.2.2 Each Party shall promptly provide the other Party with all adverse event and other
material safety information relating to Products that is or becomes known to such Party. 
 6.3 Diligence. On a Licensed Promoter-by-Licensed Promoter basis, Spark shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for and, following receipt of Regulatory
Approval, Commercialize [***] Product incorporating such Licensed Promoter in [***] the applicable Licensed Field in [***]; provided, that the Parties acknowledge that Spark’s Development, regulatory and Commercialization activities
[***]. 
 6.4 Regulatory Assistance. Senti shall reasonably assist Spark, at its reasonable request, by providing data,
documents and other information [***] by any Regulatory Authorities in connection with Spark’s Development, Manufacturing, Commercialization and other exploitation activities with respect to such Licensed Promoter at part of a Product in the
applicable Licensed Field. [***]. 
 6.5 Compliance. All activities to be conducted by or on behalf of the Parties hereunder under
this Article 6 shall be conducted in all material respects in compliance with applicable Laws, including GLP and GCP. 
 ARTICLE 7

 CONSIDERATION 

7.1 [***]. Within [***] after the Effective Date, Spark shall pay to Senti a one-time, non-refundable and non-creditable up-front payment of Three Million Dollars ($3,000,000). 

7.2 Research Support. 

7.2.1 During the Research Program, Spark will reimburse Senti for one hundred percent (100%) of the Out-of-Pocket Costs actually incurred by Senti in connection with its activities under the Research Program, in each case, in accordance with the budget included in the Research Plan (the “Research
Budget”). Within [***] after the end of each Calendar Quarter during the Research Term, Senti shall provide to Spark an invoice for the Out-of-Pocket Costs
incurred in such Calendar Quarter. All invoices for Out-of-Pocket Costs shall include [***] of all such costs (and be accompanied by relevant supporting documentation),
and Spark shall pay Senti all costs set forth therein within [***] of receipt of such invoice except to the extent that Spark disputes such invoice or a portion thereof in good faith by notice to Senti within such [***] period, in which case the
Parties shall use good faith efforts to resolve such dispute promptly and Spark shall pay the remaining amount, if any, within [***] after resolution of such dispute. 

7.2.2 During the Research Program, Spark will reimburse Senti at the FTE Rate for the costs of any FTEs actually performing activities under
the Research Plan in accordance with the Research Budget (the “FTE Costs”); provided that, [***]. Senti shall provide to Spark, within [***] after the end of each Calendar Quarter during the Research Term, a report indicating
the number of FTEs actually provided by Senti with respect to the Research Program during such Calendar Quarter. Senti shall use [***] to record the number of hours and FTEs actually applied to the Research Program, which [***]. Within [***] after
the end of each Calendar Quarter during the Research Term, Senti shall provide to Spark an invoice for the FTE Costs incurred in such Calendar Quarter, and Spark shall pay each invoice for such FTE Costs within [***] of receipt of such invoice
except to the extent that Spark disputes such invoice or a portion thereof in good faith by notice to Senti within such [***] period, in which case the Parties shall use good faith efforts to resolve such dispute promptly and Spark shall pay the
remaining amount, if any, within [***] after resolution of such dispute. 

  
 - 25 - 

 7.3 License Fee. On a Licensed Promoter-by-Licensed Promoter basis, upon exercise of the Spark Option with respect to each Licensed Promoter, Spark shall pay to Senti a one-time, non-refundable and non-creditable payment of [***] within [***] after exercise of such Spark Option. For clarity, the maximum amount payable under this
Section 7.3 is [***]. 
 7.4 Development Milestone Payments. 

7.4.1 Within [***] after the first achievement by Spark, any of its Affiliates or any Sublicensee of each of the Milestone Events set forth
below for a particular Product, Spark shall notify Senti thereof and make the corresponding payment to Senti within [***] after the achievement of such Milestone Event. Each milestone amount set forth below shall be payable no more than once per
Product, regardless of how many times such Milestone Event is achieved by such Product. For clarity, the maximum amount payable under this Section 7.4 per Product is [***]. 

 

			
	 Milestone Event
	  	 Payment

(in $ Millions)

	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

 Notwithstanding the foregoing, [***]. 

7.4.2 If any of the [***] development or regulatory Milestone Events set forth in the table above for a Product is not achieved prior to the
achievement of a subsequent Milestone Event for such Product (such non-achieved development milestone event, a “Skipped Milestone”), then such Skipped Milestone shall be [***], and the
milestone payment for such Skipped Milestone shall be [***] for such subsequent Milestone Event. 
 7.4.3 For purposes of determining whether
milestone payments are owed under this Section 7.4 and Section 7.5, a Product shall [***]; provided, that, if [***]. 

  
 - 26 - 

 7.5 Commercial Milestone Payments. 

7.5.1 Within [***] after the end of any Calendar Quarter in which a Milestone Event set forth in the table below is first achieved by Spark,
any of its Affiliates or any Sublicensee for a particular Product, Spark shall notify Senti thereof and make the corresponding payment to Senti within [***] after the end of such Calendar Quarter in which the applicable Milestone Event was achieved.
Each milestone amount set forth below shall be payable no more than once per Product. The maximum aggregate amount that can become payable under this Section 7.5 per Product is [***]. 

 

			
	 Milestone Event
	  	 Payment

(in $ millions)

	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]
		
	[***]	  	[***]

 7.5.2 The milestone payments set forth in Section 7.5.1 for a given Product (each, a
“Commercial Milestone Payment”) shall [***]. 
 7.6 Royalties. 

7.6.1 Royalty Rate. Subject to the remainder of this Section 7.6, on a
Product-by-Product and country-by-country basis, during the applicable Royalty Term,
Spark shall pay to Senti running royalties at a rate of [***] of the aggregate Net Sales of such Product in such country. Following the expiration of a particular Royalty Term with respect to such Product and country to which such Royalty Term is
related, (a) the license to Spark set forth in Section 5.1.2 shall become [***] with respect to such Product in such country and (b) sales of such Product in such country shall be excluded in determining Net Sales
of such Product. 
 7.6.2 Deductions. Subject to Section 7.6.3: 

(a) [***]. 
 (b) [***]. 

7.6.3 Limitation. In no event shall the rate of royalties payable to Senti with respect to a given Product in a country in accordance
with this Agreement be reduced under this Section 7.6 [***] of the Net Sales of such Product in such country in any Calendar Quarter; provided that any such reductions [***]. 

7.7 Reports and Payments. Within [***] after the end of each Calendar Quarter, Spark shall deliver to Senti a report
setting forth for such Calendar Quarter the following information, on a Product-by-Product and country-by-country basis: (a) the gross sales and Net Sales for such Product, (b) details of any deductions from gross sales taken in accordance with
Section 1.45 and any royalty reductions made pursuant to Section 7.6.2; and (c) the royalty amount due hereunder for the Net Sales of such Product. No such reports shall be due for any Product before the First
Commercial Sale of such Product in the Territory. The total royalty due for the sale of Products during such Calendar Quarter shall be remitted no later than [***] after the end of such Calendar Quarter. 

  
 - 27 - 

 7.8 Payment Method; Late Payments. Payments hereunder shall be paid by wire
transfer, or electronic funds transfer (EFT) in immediately available funds to a bank account designated by Senti at least [***] in advance of such payment. Overdue payments shall bear interest at a rate equal [***]. The interest payment shall be
due from the day the original payment was due until the day that the payment was received by Senti. The payment of such interest shall not restrict Senti from exercising any other rights it may have because any payment is overdue. 

7.9 Currency. All amounts payable and calculations hereunder shall be in Dollars. Conversion of sales recorded in local currencies to
Dollars will first be determined in the foreign currency of the country in which such Products are sold and then converted to Dollars at [***] for conversion of the foreign currency into Dollars on the last day of the Calendar Quarter for which such
payment is due. 
 7.10 Taxes. 

7.10.1 Withholding Taxes. All payments due under this Agreement will be made without any deduction or withholding for or on account of
any tax unless such deduction or withholding is required by Law to be assessed against Senti. If Spark is so required to deduct or withhold, Spark will (a) promptly notify Senti of such requirement, (b) pay to the relevant authorities the full
amount required to be deducted or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such amount has been assessed against Senti, and (c) promptly forward to Senti an
official receipt (or certified copy) or other documentation reasonably acceptable to Spark, to the extent available, evidencing such payment to such authorities. 

7.10.2 [***]. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double
taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted. 

7.10.3 Indirect Taxes. Except as otherwise provided in this Section 7.10, each Party shall be liable
for and shall pay the taxes which are imposed on it under applicable Law arising from, or attributable to, any payments due under this Agreement. 

7.11 Maintenance of Records. Each Party shall keep, and shall cause its Affiliates and, with respect to Spark, its Sublicensees
to keep, accurate books and accounts of record in connection with, with respect to Spark, the calculation of payments to be made by Spark or, with respect to Senti, Research Program costs under this Agreement in sufficient detail to permit accurate
determination of all figures necessary for the other Party’s verification of payments to be paid under this Agreement. Each Party and its Affiliates and, with respect to Spark, its Sublicensees shall maintain such records for a period of at
least [***] after the end of the Calendar Year in which they were generated, or longer, if and to the extent required by applicable Law. 

  
 - 28 - 

 7.12 Audits. Each Party shall have the right, at such Party’s own expense and no
more than once per Calendar Year, to have an independent, certified public accountant of national standing, selected by the auditing Party and reasonably acceptable to the audited Party, review all records maintained in accordance with
Section 7.11 upon reasonable notice and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of payments required and made under this Agreement within the
prior [***] period; provided, that, prior to initiating any such review, such accountant shall enter into a confidentiality agreement on customary terms with the audited Party. No Calendar Quarter may be audited more than one time. The
auditing Party shall receive a copy of each audit report promptly from the other Party. The audited Party shall pay the full cost of the inspection unless the discrepancy is greater than [***] of the amount paid for the applicable Calendar Year that
is the subject of such inspection, in which case the auditing Party shall pay to the audited Party the reasonable and documented cost charged by such accountant for such inspection. If such audit shows a discrepancy in the audited Party’s
favor, the auditing Party shall pay the audited Party the amount of the discrepancy within [***] after being notified thereof. 
 ARTICLE
8 
 INTELLECTUAL PROPERTY MATTERS 

8.1 Ownership. 
 8.1.1
Background IP. Each Party shall retain all right, title and interest in and to any Patent Rights or Know-How Controlled by such Party as of the Effective Date, or developed or acquired by such
Party after the Effective Date and independently of this Agreement, and nothing in this Agreement shall assign any ownership to the other Party with respect to such Patent Rights or Know-How. 

8.1.2 Foreground IP. 
 (a)
Senti Platform Improvements. Senti shall own all right, title and interest in and to any Patent Right or Know-How that (i) is conceived, developed or reduced to practice by or on behalf of one or
more Parties, Affiliates or sublicensees during the course of, arising out of or as a result of activities under this Agreement and (ii) constitutes an improvement to, or an enhancement or modification of, any element of the Senti Platform
(each such Patent Right or Know-How, a “Senti Platform Improvement”); provided, however, that Senti Platform Improvements shall [***]. Spark hereby assigns to Senti all right,
title and interest in all Senti Platform Improvements. Spark shall obtain rights needed from its Affiliates and Sublicensees to effectuate such assignment. 

(b) Promoter Improvements. 

(i) Senti shall own all right, title and interest in and to any Patent Right or Know-How that
(A) is conceived, developed or reduced to practice by or on behalf of one or more Parties, any of their Affiliates or any of their sublicensees during the course of, arising out of or as a result of activities under this Agreement and
(B) constitutes an improvement to, or an enhancement or modification of, any Option Promoter or Licensed Promoter [***] (each such Patent Right or Know-How, a “Promoter Improvement”);
provided, however, that Promoter Improvements shall [***]. Spark hereby assigns to Senti all right, title and interest in all Promoter Improvements. Spark shall obtain rights needed from its Affiliates and Sublicensees to effectuate
such assignment. Spark shall disclose all Promoter Improvements to Senti through regularly-scheduled meetings of the Joint Patent Working Group, and the Parties shall [***]. 

  
 - 29 - 

 (ii) [***] all right, title and interest in and to any Patent Right or Know-How that (A) is conceived, developed or reduced to practice by or on behalf of [***] during the course of, arising out of or as a result of activities under this Agreement, (B) constitutes an
improvement to, or an enhancement or modification of, any Option Promoter or Licensed Promoter [***], and (C) is not a Promoter Improvement (each such Patent Right or Know-How, a “Promoter
Change”); provided, however, that Promoter Changes shall [***]. The Parties shall have the rights and obligations set forth in Section 8.1.2(d) with respect to Promoter Changes except that neither
Party nor any of its Affiliates shall practice, or authorize any Third Party to practice, such Patent Right or Know-How after the termination of this Agreement without the consent of the other Party [***].
[***] Spark shall disclose all Promoter Changes to Senti through regularly-scheduled meetings of the Joint Patent Working Group, and the Parties shall [***]. 

(iii) For clarity, if the claims of any Patent Right that is conceived, developed or reduced to practice by or on behalf of Spark, any of its
Affiliates or any of its sublicensees during the course of, arising out of or as a result of activities under this Agreement recite a Product comprising a Licensed Promoter and one or more other component(s) (such as the gene whose transcription is
regulated by such Licensed Promoter), wherein [***], then such Patent Right shall be [***]. By comparison, if the claims of any Patent Right that is conceived, developed or reduced to practice by or on behalf of Spark, any of its Affiliates or any
of its sublicensees during the course of, arising out of or as a result of activities under this Agreement recite such a Product wherein [***], such Patent Right shall [***], and the ownership thereof shall be determined in accordance with
Section 8.1.2(c) or Section 8.1.2(d). If a Licensed Promoter is [***], then any Patent Right that is conceived, developed or reduced to practice by or on behalf of [***] during the course of,
arising out of or as a result of activities under this Agreement and [***] shall be jointly owned by Senti and Spark and deemed to be a Joint Patent Right if [***] and, in such case, the Parties shall have the rights and obligations with set forth
in Section 8.1.2(d) with respect thereto; provided, that neither Party nor any of its Affiliates shall practice, or authorize any Third Party to practice, such Patent Right after the termination of this Agreement
without the consent of the other Party [***]. 
 (c) Sole Foreground IP. Subject to Section 8.1.2(a) and
Section 8.1.2(b), as between the Parties, each Party shall own all right, title and interest in and to any Patent Rights or Know-How solely conceived, developed or reduced to practice
by or on behalf of such Party or its Affiliates or sublicensees during the course of, arising out of or as a result of activities under this Agreement. 

(d) Joint Foreground IP. Subject to Section 8.1.2(a) and Section 8.1.2(b), the
Parties shall have an undivided one-half right, title and interest in and to any Patent Rights or Know-How that is jointly conceived, developed or reduced to practice by
or on behalf of the Parties (or their Affiliates or in the case of Spark, Sublicensees) during the course of, arising out of or as a result of activities under this Agreement. Subject to Section 5.1.2, neither Party shall
have any obligation to account to the other Party for profits, or to obtain any consent of the other Party to license, assign its joint interest, or exploit any such jointly owned Patent Rights or Know-How, by reason of joint ownership thereof. Each
Party hereby waives any right it may have under the laws of any jurisdiction to require any such consent or accounting. 

  
 - 30 - 

 (e) Inventorship. Inventorship shall be determined in accordance with the patent
laws of the United States. 
 8.2 Prosecution and Maintenance of Patents. 

8.2.1 Subject to Section 8.2.2, Section 8.2.3 and Section 8.2.4,
(a) each Party shall have the right, but not the obligation, at its sole expense to Prosecute and Maintain Patent Rights solely owned by such Party in accordance with Section 8.1 and (b) the Parties shall, through the
Joint Patent Working Group, mutually agree on the Prosecution and Maintenance of Patent Rights that are jointly owned by the Parties in accordance with Section 8.1 (collectively, the “Joint Patent Rights”).

 8.2.2 Following exercise of the Spark Option with respect to a particular Licensed Promoter, Spark shall have the first right to Prosecute
and Maintain any Senti Patent Rights that [***] (the “Spark Responsibility Patents”), including as set forth in Section 8.2.4, using counsel reasonably acceptable to Senti, at Spark’s sole cost and
expense. Spark shall keep Senti apprised of the status of the Prosecution and Maintenance of each Spark Responsibility Patent and shall promptly provide Senti with material correspondences received from any patent authorities in connection
therewith. Further, Spark shall promptly provide Senti with drafts of all proposed material filings and correspondences to any patent authorities with respect to the Spark Responsibility Patents for Senti’s review and comment prior to the
submission of such proposed filings and correspondences, and shall give reasonable consideration to any such comments promptly provided by Senti in connection therewith. If Spark decides to abandon or cease the Prosecution or Maintenance of any
Spark Responsibility Patent, it shall promptly notify Senti thereof (in any event no later than [***] prior to the next deadline for any action in the relevant patent authority). Senti shall thereafter have the right, but not the obligation, to
assume the Prosecution and Maintenance of such Spark Responsibility Patent, by counsel of its own choice, at Senti’s cost and expense. 

8.2.3 Following exercise of the Spark Option with respect to a particular Licensed Promoter, Senti shall have the first right to Prosecute and
Maintain any Senti Patent Rights, [***] (the “Senti Responsibility Patents”) using counsel reasonably acceptable to Spark, at Senti’s sole cost and expense. Senti shall keep Spark apprised of the status of each Senti
Responsibility Patent and shall promptly provide Spark with material correspondences received from any patent authorities in connection therewith. Further, Senti shall promptly provide Spark with drafts of all proposed material filings and
correspondences to any patent authorities with respect to the Senti Responsibility Patents for Spark’s review and comment prior to the submission of such proposed filings and correspondences and shall give reasonable consideration to any such
comments promptly provided by Spark in connection therewith. If Senti decides to abandon or cease the Prosecution or Maintenance of any Senti Responsibility Patent, it shall promptly notify Spark thereof (in any event no later than [***] prior to
the next deadline for any action in the relevant patent authority). Spark shall thereafter have the right, but not the obligation, to assume the Prosecution and Maintenance of such Senti Responsibility Patent, by counsel of its own choice, at
Spark’s cost and expense. 

  
 - 31 - 

 8.2.4 The Parties, through the Joint Patent Working Group, shall coordinate patent strategy
with respect to Senti Patent Rights. Without limiting the generality of the foregoing, with respect to each Licensed Promoter, upon Spark’s reasonable request and at Spark’s sole cost and expense, the Joint Patent Working Group shall, to
the extent possible, [***]. 
 8.3 Defense of Third Party Infringement Claims. The Parties’ rights and obligations pursuant to
this Section 8.3 are subject to the Parties’ respective indemnification rights and obligations pursuant to Article 11. If, following Spark’s exercise of the Spark Option for a Licensed Promoter, the
Development, Manufacture, Commercialization or other exploitation of a Product incorporating such Licensed Promoter in the Licensed Field in the Territory becomes the subject of a Third Party’s claim or assertion of infringement of a Patent
Right (each, an “Infringement Claim”), the Party first having notice of the claim or assertion shall promptly notify the other Party thereof. Unless the Parties otherwise agree in writing, Spark shall have the right to defend any
Infringement Claim at its sole cost and expense, and Senti shall reasonably assist Spark and cooperate in any such litigation at Spark’s request and expense. Senti may participate in any such claim, suit or proceeding, by counsel of its choice,
at its own cost and expense. Spark shall keep Senti reasonably informed with respect to the progress of any such litigation. If Spark decides not to defend or control the defense of, or otherwise fails to initiate or maintain the defense of, any
such Infringement Claim within [***] of notice thereof, then Senti will be entitled to take over, at its option, the right to conduct and control the defense of such Infringement Claim, at Senti’s sole cost and expense. 

8.4 Enforcement of Spark Responsibility Patents. 

8.4.1 Each Party will provide to the other Party written notice within [***] after becoming aware of any infringement, unauthorized use,
misappropriation or threatened infringement (“Infringement”) of any Spark Responsibility Patent by a Third Party that is actually or potentially exploiting [***] (“Competitive Infringement”). 

8.4.2 As between the Parties, following Spark’s exercise of the Spark Option for a Licensed Promoter, Spark will have the first right, but
not the obligation, to enforce any Spark Responsibility Patents against any Competitive Infringement of a Product incorporating such Licensed Promoter, by counsel of its own choice, at its own cost and expense. If Spark prosecutes any such
Competitive Infringement, Senti shall have the right to join as a party to such claim, suit or proceeding in the Territory and participate, by its own counsel, at its own cost and expense. If, within [***] after receipt of notice of any Competitive
Infringement, Spark has not taken reasonable steps to enforce the Spark Responsibility Patents against such Competitive Infringement, then, upon written notice to Spark, Senti will have the right, but not the obligation, to enforce such Spark
Responsibility Patents against such Competitive Infringement, by counsel of its own choice, at its own cost and expense. 
 8.5 Other
Enforcement of Actions. 
 8.5.1 Each Party will provide to the other Party written notice within [***] after becoming aware of any
Infringement of any Joint Patent Rights that are not Spark Responsibility Patents or Senti Responsibility Patents, and thereafter, the Parties will, through the Joint Patent Working Group, coordinate regarding any enforcement action with respect to
such Infringement; provided, that, if such Infringement is by a Third Party that is actually or potentially exploiting [***], then (i) Senti will have the first right, but not the obligation, to enforce any such Joint Patent Rights
against such Infringement, by counsel of its own choice, at its own cost and expense, (ii) if Senti prosecutes any such Infringement, Spark shall have the right to join as a party to such claim, suit or proceeding in the Territory and
participate, by its own counsel, at its own cost and expense, and (iii) if, within [***] after receipt of notice of any such Infringement, Senti has not taken reasonable steps to enforce the Joint Patent Rights against such Infringement, then,
upon written notice to Senti, Spark will have the right, but not the obligation, to enforce such Joint Patent Rights against such Infringement, by counsel of its own choice, at its own cost and expense. 

  
 - 32 - 

 8.5.2 Each Party will provide to the other Party written notice within [***] after becoming
aware of any Infringement of any Senti Responsibility Patents. Senti will have the right, but not the obligation, to enforce any Senti Responsibility Patents against any Infringement; provided, that, if such Infringement is a Competitive
Infringement and Senti does not take reasonable steps to enforce such Senti Responsibility Patent against such Competitive Infringement within [***] after receipt of notice of any such Competitive Infringement, then, upon written notice to Senti and
subject to Senti’s prior written consent (such consent not to be unreasonable withheld), Spark will have the right, but not the obligation, to enforce such Senti Responsibility Patent against such Competitive Infringement, by counsel of its own
choice, at its own cost and expense. 
 8.6 Cooperation. Each Party will cooperate with the other Party to the extent reasonably
necessary for a Party to bring any enforcement action pursuant to Section 8.4 or Section 8.5, as applicable, at the enforcing Party’s request, cost and expense. The enforcing Party shall keep
the non-enforcing Party reasonably informed of all material developments in connection with such enforcement action and reasonably consider the non-enforcing
Party’s comments in connection therewith. The non-enforcing Party will, and will cause its Affiliates to, assist the enforcing Party, as the enforcing Party may reasonably request from time to time, in
connection with any enforcement action pursuant to Section 8.4 or Section 8.5, as applicable, including joining in, or being named as a necessary party to, any such enforcement action and executing
any settlement agreement as reasonably requested by the enforcing Party; provided that the enforcing Party will reimburse the non-enforcing Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection its cooperation pursuant to this sentence. Unless otherwise set forth herein, the enforcing Party will have the right
to settle all claims arising from any such enforcement action; provided that neither Party will have the right to settle any litigation or claim under this Section 8.6 in a manner that (a) imposes any costs or
liability on the other Party or its Affiliates or its or their licensees, (b) involves any admission of wrongdoing, fault, or liability by the other Party or its Affiliates or its or their licensees, (c) admits the invalidity or
unenforceability (in whole or in part) of intellectual property Controlled by the other Party or its Affiliates or its or their licensees, or (d) imposes restrictions or obligations on the other Party or its Affiliates or licensees not
otherwise permitted under this Agreement, in each case ((a) through (d)), without the express written consent of such other Party, which shall not be unreasonably withheld, conditioned, or delayed. 

8.7 Recoveries. Any recovery received as a result of any action pursuant to Section 8.3,
Section 8.4 or Section 8.5 shall be used first to reimburse the Parties’ costs and expenses (including attorneys’ and professional fees) incurred in connection with such action (and if
such recoveries are insufficient to cover all such costs and expenses, on a pro rata basis), then the remainder of the recovery shall be allocated as follows: 

  
 - 33 - 

 8.7.1 for any action brought pursuant to Section 8.5, any such
remainder of the recovery shall be [***]; 
 8.7.2 for any action brought by Senti pursuant to Section 8.3
or Section 8.4.2, any such remainder of the recovery shall be [***]; and 
 8.7.3 for any action brought by Spark
pursuant to Section 8.3 or Section 8.4.2, any such remainder of recovery [***]. 

ARTICLE 9 

CONFIDENTIALITY 
 9.1
Treatment of Confidential Information. 
 9.1.1 During the Term and for [***] thereafter, each Receiving Party
shall maintain the Confidential Information of the Disclosing Party in confidence, shall not disclose, divulge or otherwise communicate such Confidential Information to others and shall not use it for any purpose other than in performance of its
obligations or exercise of its rights pursuant to this Agreement, except that: 
 (a) each Receiving Party may disclose the Disclosing
Party’s Confidential Information to the Receiving Party’s Affiliates or their respective Representatives who are bound by written or professional obligations of confidentiality and restrictions on use substantially equivalent to those set
forth in this Article 9 and who have a need to know such information to perform obligations or exercise rights on behalf of the Receiving Party; and 

(b) each Receiving Party or its Affiliates may disclose Confidential Information of the Disclosing Party: 

(i) to Governmental Authorities, to the extent necessary to obtain or maintain Regulatory Approvals for any Product (or, in the case of Senti,
any product comprising a Licensed Promoter other than any Product for use in the Licensed Field) as permitted under this Agreement; 
 (ii)
to the Receiving Party’s or any of its Affiliates’ outside consultants, service providers, scientific advisory boards, managed care organizations, non-clinical and clinical investigators, licensees,
sublicensees and potential licensees and sublicensees, in each case to the extent necessary to Develop, Manufacture, Commercialize or otherwise exploit any Product in the Licensed Field in accordance with this Agreement; provided that such
Receiving Party or its applicable Affiliate(s) or sublicensees shall bind such Third Parties to written obligations of confidentiality and restrictions on use substantially equivalent to those set forth in this Article 9;

 (iii) under written or professional obligations of confidentiality and restrictions on use substantially equivalent to those set forth in
this Article 9 (except that the duration of such obligations and restrictions may be shorter; provided that they extend for at least [***] from the date of disclosure), to the Receiving Party’s or its Affiliates’ bona fide
potential or actual acquirers, assignees permitted under Section 14.6, investors, lenders, investment bankers or other financing sources or financial partners; and 

  
 - 34 - 

 (iv) to the extent necessary to Prosecute and Maintain, defend or enforce Senti Technology
in accordance with this Agreement. 
 9.2 Exceptions. Notwithstanding the foregoing, the Receiving Party’s obligations
under Section 9.1 shall not apply to, and “Confidential Information” shall exclude, any portion of any information of the Disclosing Party that, as shown by competent evidence: 

9.2.1 either before or after the date of the disclosure by or on behalf of the Disclosing Party or its Affiliate to the Receiving Party or its
Affiliate, is lawfully disclosed to the Receiving Party or its Affiliate by a Third Party, other than on behalf of the Disclosing Party or its Affiliate, without any violation of any obligation to the Disclosing Party or any of its Affiliates; 

9.2.2 was known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use,
prior to disclosure to the Receiving Party or any of its Affiliates; 
 9.2.3 either before or after the date of the disclosure by or on
behalf of the Disclosing Party or its Affiliate to the Receiving Party or its Affiliate, becomes published or generally known to the public through no fault or omission on the part of the Receiving Party, its Affiliates or their respective
Representatives; or 
 9.2.4 is independently developed by or on behalf of the Receiving Party or any of its Affiliates outside of the
activities contemplated by this Agreement without reference to or reliance upon the Disclosing Party’s or any of its Affiliates’ Confidential Information, as demonstrated by contemporaneous written records of the Receiving Party or its
applicable Affiliate(s). 
 9.3 Disclosures by Law. The Receiving Party or any of its Affiliates may disclose Confidential Information
of the Disclosing Party or any of its Affiliates to the extent such disclosure is required in order for the Receiving Party or any of its Affiliates to comply with applicable Laws or legal process, including the rules or regulations of the U.S.
Securities and Exchange Commission, or similar agency in any country other than the United States, or of any stock exchange, including Nasdaq, or to defend or prosecute litigation; provided that the Receiving Party (a) promptly provides
prior notice, to the extent practicable, of such disclosure to the Disclosing Party, (b) cooperates with the Disclosing Party, at the Disclosing Party’s request and expense, to take whatever action the Disclosing Party may deem appropriate
to protect the confidentiality of such information, and (c) furnishes only that portion of the Disclosing Party’s Confidential Information that the Receiving Party or its Affiliates is legally required to furnish. 

9.4 Publication Rights. 

9.4.1 [***], neither Party will make any Publication disclosing any Results [***] review in accordance with
Section 9.4.5. 

  
 - 35 - 

 9.4.2 [***], neither Party will make any Publication disclosing the Results [***] or any
results, data or finding generated pursuant to the Evaluation Program [***], in each case, [***] review in accordance with Section 9.4.5. 

9.4.3 [***], (a) Spark shall have the right to make Publications disclosing the Results [***], any results, data or finding generated pursuant
to the Evaluation Program [***] or the Development, Manufacturing, Commercialization or other exploitation of Products [***] in the Licensed Field in the Territory under this Agreement, [***] review in accordance with
Section 9.4.5 and (b) Senti shall have the right to make Publications disclosing the Development, Manufacturing, Commercialization or other exploitation of (i) Products [***] outside the Licensed Field in the
Territory and (ii) products [***] that are not Products, in each case, [***] review in accordance with Section 9.4.5. 

9.4.4 [***], Senti shall have the right to make Publications disclosing the Results [***] or any results, data or finding generated pursuant to
the Evaluation Program [***] review in accordance with Section 9.4.5 ([***]). 
 9.4.5 If either Party intends to
make a Publication described in Sections 9.4.1-9.4.4, such Party (the “Publishing Party”) shall provide the other Party (the “Non-Publishing Party”) with such
proposed Publication at least [***] prior to the intended submission or presentation date, whichever is sooner. The Non-Publishing Party will have the right to reasonably review and comment to such Publication
and the Publishing Party shall in good faith consider any comments made by the Non-Publishing Party in such [***] period. If such Publication contains Confidential Information of the Non-Publishing Party, then upon the Non-Publishing Party’s request during such [***] period, the Publishing Party shall delete any such information identified by the Non-Publishing Party. If the Non-Publishing Party wishes to request a reasonable delay of the Publication in order to protect patentable information, the Publishing Party
shall delay the Publication for a period of no more than [***] to enable patent applications to be filed in accordance with ARTICLE 8 to protect any intellectual property rights disclosed in such Publication. For clarity, if the Non-Publishing Party fails to notify the Publishing Party during the [***] previewing period as provided under this Section 9.4.5, the Publishing Party shall be free to proceed with the
proposed Publication. 
 9.4.6 For the avoidance of doubt, this Section 9.4 shall in no way prohibit (a) Spark
from making Publications with respect to any product that is not a Product or (b) Senti from making Publications with respect to any Senti products that do not incorporate a Licensed Promoter. 

9.5 Return of Confidential Information. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party or, at the Disclosing Party’s request, destroy all of the Disclosing Party’s or any of its Affiliates’ Confidential Information and all copies and reproductions thereof. Notwithstanding the foregoing, (a) the
Receiving Party may retain one (1) copy of the Disclosing Party’s or any of its Affiliates’ Confidential Information for archival purposes, (b) the Receiving Party and its Affiliates may retain and use, and disclose in accordance
with Section 9.1, the Disclosing Party’s or any of its Affiliates’ Confidential Information solely to the extent reasonably necessary to exercise the rights and licenses of the Receiving Party expressly surviving
expiration or termination of this Agreement, (c) the Receiving Party shall not be required to return or destroy the Disclosing Party’s or any of its Affiliates’ Confidential Information stored on automatically created system-back-up media, and (d) the Receiving Party shall not be required to return or destroy the Disclosing Party’s or any of its Affiliates’ Confidential Information that the Receiving Party or any
of its Affiliates is required by Law to maintain. Notwithstanding the return or destruction of the Disclosing Party’s or any of its Affiliates’ Confidential Information, the Receiving Party shall continue to be bound by its obligations of
confidentiality and other obligations under this Article 9 with respect to such Confidential Information. 

  
 - 36 - 

 9.6 Press Release; Terms of this Agreement; Use of Names. 

9.6.1 Press Releases. Following the Effective Date, Senti may issue a press release in the form of Exhibit F-1 hereto, and Spark may issue a press release in the form of Exhibit F-2 hereto. Other than the press releases set forth on Exhibit F-1 and Exhibit F-2, neither Party shall issue any press releases or other forms of publicity regarding the status of or activities performed pursuant to this
Agreement without the prior written consent of the other Party, except that [***]; provided, that, with respect to any press release or other form of publicity contemplated by [***], (x) Senti shall provide Spark with drafts of any such
proposed press release or other form of publicity for Spark’s review and comment prior to the issuance thereof, (y) Senti shall delay issuing such press release or other form of publicity until the [***], and (z) such press release or
other form of publicity shall [***]; provided, that, for clarity, Senti shall [***]. For the avoidance of doubt, this Section 9.6.1 shall in no way prohibit (1) Spark from issuing press releases or other forms
of publicity with respect to any product developed or commercialized by or on behalf of Spark, independent of Senti or (2) Senti from issuing press releases or other forms of publicity with respect to any product developed or commercialized by
or on behalf of Senti, independent of Spark. 
 9.6.2 Terms of Agreement. Either Party shall be permitted to disclose the terms
of this Agreement to the extent required to comply with applicable Laws or legal process, including the rules or regulations of the U.S. Securities and Exchange Commission, or similar agency in any country other than the United States, or of any
stock exchange, including Nasdaq. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof, the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this
Agreement with respect to any filings with the U.S. Securities and Exchange Commission or similar agency in any country other than the United States, or of any stock exchange, including Nasdaq, on which securities issued by a Party or a Party’s
Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party; provided that the Parties
will use commercially reasonable efforts to file redacted versions with any governing bodies that are consistent with the Redacted Version. Each Party may also disclose the terms of this Agreement to the extent permitted for disclosures of
Confidential Information under Section 9.1.1. Neither Party shall disclose the terms of this Agreement, except as expressly authorized by the terms of this Section 9.6.2. 

9.6.3 Use of Names. Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity
or news release relating to this Agreement or its subject matter without the prior express written permission of the other Party. 

  
 - 37 - 

 ARTICLE 10 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

10.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as of the Effective Date as
follows: 
 10.1.1 it is duly organized and validly existing under the Laws of its jurisdiction of organization and has the corporate or
organizational power and authority to execute and deliver this Agreement and to carry out its obligations hereunder; 
 10.1.2 (a) the
execution, delivery and performance of this Agreement by such Party has been duly and validly authorized and approved by proper corporate or organizational action on the part of such Party; (b) it has taken all other action required by
applicable Law, its certificate of organization, certificate of formation or by-laws, as applicable, and any agreement to which it is a party or by which it or its assets are bound, to authorize such
execution, delivery and performance; and (c) assuming due authorization, execution and delivery on the part of the other Party, this Agreement constitutes a legal, valid and binding obligation of such Party; and 

10.1.3 neither the execution and delivery of this Agreement nor the performance hereof by such Party will result in the breach of or give rise
to any conflict, termination of, rescission, renegotiation or acceleration under or trigger any other rights under any agreement or contract to which such Party may be a party as of the Effective Date. 

10.2 Mutual Covenants of the Parties. Each Party hereby covenants to the other Party as follows: 

10.2.1 Compliance with Applicable Laws. Each Party and its Affiliates shall conduct, and shall cause its sublicensees, contractors, and
consultants to conduct, all of its activities contemplated under this Agreement in accordance with all applicable Laws. 
 10.2.2 No
Debarment. Neither Party nor any of its Affiliates will use in any capacity, in connection with the Development, Manufacture, Commercialization or other exploitation of any Product, any Person who has been Debarred. Each Party shall inform the
other Party in writing immediately upon becoming aware that any Person who is serving or has served in any capacity in connection with the Development, Manufacture, Commercialization or other exploitation of any Product is Debarred, or if any Claim
is pending or, to the best of such Party’s knowledge, is threatened, relating to the Debarment of such Party or any Person used in any capacity by such Party or any of its Affiliates in connection with the Development, Manufacture,
Commercialization or other exploitation of any Product. 
 10.3 Senti’s Representations and Warranties. Senti
hereby represents and warrants to Spark (a) as of the Effective Date and (b) except as otherwise set forth in a disclosure schedule delivered to Spark concurrently with the Data Package for a particular Promoter Profile, as of the delivery
date of such Data Package (each, a “Data Package Delivery Date”), as follows: 
 10.3.1 It is the sole and exclusive owner
of or otherwise Controls the Senti Technology to be licensed to Spark hereunder, free and clear of all Encumbrances; 

  
 - 38 - 

 10.3.2 The Data Package for each Promoter Profile sets forth, as of the Data Package
Delivery Date, a complete and accurate list of all Senti Patent Rights with respect to Option Promoters having the applicable Promoter Profile that specifies whether such Senti Patent Rights are owned or otherwise Controlled by Senti, and, in the
case of in-licensed Senti Patent Rights, includes a reference to the relevant Senti Third Party Agreement; 

10.3.3 As of the Data Package Delivery Date for a particular Promoter Profile, to Senti’s knowledge, [***]; 

10.3.4 Senti has full legal rights and authority to grant the option, licenses and other rights under the Senti Technology granted to Spark
under this Agreement and has not assigned, transferred, conveyed or licensed its right, title and interest in the Senti Technology in any manner [***]; 

10.3.5 it has received no written notice of or any written demand relating to any threatened or pending litigation which would reasonably
[***]; 
 10.3.6 Senti has not given any written notice to any Third Party asserting infringement by such Third Party of any of the Senti
Technology and, to Senti’s knowledge, there is no unauthorized use, infringement or misappropriation of the Senti Technology; and 

10.3.7 Senti has used commercially reasonable efforts to [***]; and 

10.3.8 neither Senti nor any of its Affiliates is party to any agreement or other arrangement pursuant to which Senti or any such Affiliate
[***] Senti Technology. 
 10.4 Senti’s Covenants. Senti hereby covenants to Spark that: 

10.4.1 Senti will not assign, transfer, convey or otherwise grant to any Person any rights to any Senti Technology in any manner [***]; and

 10.4.2 Senti will not [***] the Senti Technology. 

10.5 No Other Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 10.1 OR SECTION 10.3 OF THIS AGREEMENT,
NEITHER PARTY MAKES ANY REPRESENTATION AND NEITHER PARTY EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING ANY PRODUCT OR INTELLECTUAL PROPERTY LICENSED
HEREUNDER), INCLUDING ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. EACH PARTY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE RESEARCH AND DEVELOPMENT, MANUFACTURE, COMMERCIALIZATION OR OTHER EXPLOITATION
OF PRODUCTS PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL. 

  
 - 39 - 

 ARTICLE 11 

INDEMNIFICATION, INSURANCE AND RELEASE 

11.1 Indemnification by Spark. Spark shall indemnify, hold harmless and defend Senti, its Affiliates and their respective directors,
officers, employees, consultants and agents (collectively, the “Senti Indemnitees”) from and against any and all Losses arising from any Claim brought by a Third Party (a “Third Party Claim”) against a Senti
Indemnitee resulting from (a) [***]; (b) the Development, Manufacture, Commercialization or other exploitation of any Product by or on behalf of Spark, its Affiliates or Sublicensees (including product liability and patent infringement
claims), (c) the breach of any of Spark’s representations or warranties hereunder or any other breach of this Agreement by Spark, (d) the negligence or willful misconduct of any Spark Indemnitee, or (e) any violation of
applicable Law by any Spark Indemnitee, except in each case ((a)-(e)) to the extent that Senti is obligated to indemnify any Spark Indemnitee pursuant to Section 11.2 for such Third Party Claim. 

11.2 Indemnification by Senti. Senti shall indemnify, hold harmless and defend Spark, its Affiliates and their respective directors,
officers, employees, consultants and agents (collectively, the “Spark Indemnitees”) from and against any and all Losses arising from any Third Party Claim against a Spark Indemnitee from (a) [***]; (b) the Development, Manufacture,
Commercialization or other exploitation of any Product outside the Licensed Field or any product incorporating a Licensed Promoter that is not a Product, in each case, by or on behalf of Senti, its Affiliates or licensees (including product
liability and patent infringement claims), (c) the breach of any of Senti’s representations or warranties hereunder or any other breach of this Agreement by Senti, (d) the negligence or willful misconduct of any Senti Indemnitee, or
(e) any violation of applicable Law by any Spark Indemnitee, except in each case ((a)-(e)) to the extent that Spark is obligated to indemnify any Senti Indemnitee pursuant to Section 11.1 for such Third Party Claim.

 11.3 Procedure. The obligations to indemnify, defend, and hold harmless set forth in Sections 11.1 and 11.2 shall be
contingent upon the Indemnitee: (a) notifying the indemnifying Party of a claim, demand or suit within [***] of receipt of same; provided, however, that the Indemnitee’s failure or delay in providing such notice shall not
relieve the indemnifying Party of its indemnification obligation except to the extent the indemnifying Party is prejudiced thereby; (b) allowing the indemnifying Party or its insurers the right to assume direction and control of the defense of
any claim, demand or suit; (c) using its best efforts to cooperate with the indemnifying Party or its insurers, at the indemnifying Party’s request and expense, in the defense of such claim, demand or suit; and (d) not settling or
compromising any claim, demand or suit without prior written authorization of the indemnifying Party (not to be unreasonably withheld). The indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim,
demand or suit and will not settle or otherwise resolve such claim, demand or suit without the Indemnitee’s prior written consent, which will not be unreasonably withheld, conditioned or delayed; provided that such consent will
not be required with respect to any settlement involving only the payment of monetary awards for which the indemnifying Party will be fully-responsible (and does not admit any fault, wrongdoing or damages of the Indemnitee). The Indemnitee shall
have the right, at the Indemnitee’s expense, to employ one separate counsel and to participate in the defense of such claim, demand or suit; provided that the indemnifying Party shall bear the reasonable fees, costs and expenses of one
such separate counsel and participation if the Indemnitee shall have reasonably determined, after consultation with counsel, that an actual or potential conflict of interest makes representation by the same counsel or the counsel selected by the
indemnifying Party inappropriate. 

  
 - 40 - 

 11.4 No Consequential Damages. IN NO EVENT SHALL EITHER SENTI OR SPARK OR ANY OF
THEIR RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES OR LOSS OF PROFITS OR OPPORTUNITIES (UNLESS SUCH LOSSES ARE DIRECT DAMAGES) OR DIMINUTION OF GOODWILL ARISING OUT OF THIS
AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY; PROVIDED, HOWEVER, THAT NOTHING IN THIS SECTION 11.4 IS INTENDED TO LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS
ARTICLE 11 (B) [***]; OR (C) THE LIABILITY OF EITHER PARTY FOR DEATH OR PERSONAL INJURY CAUSED BY NEGLIGENCE OR WILLFUL MISCONDUCT. 

11.5 Insurance. During the Term, each Party shall obtain and maintain commercial general liability insurance with a reputable, solvent
insurer in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for its obligations under this Agreement, and Spark shall obtain and maintain product liability insurance and Clinical Trial
liability insurance with limits of at least [***] per occurrence and in annual aggregate. After the Term, until at least [***] after the last commercial sale of any Product, Spark shall obtain and maintain product liability insurance (or
discontinued product liability insurance) and Clinical Trial liability insurance with limits of at least [***] per occurrence and in annual aggregate, or alternatively, if coverage is written on a claims made basis, Spark shall purchase an extended
reporting period of at least [***] after last commercial sale of any Product. Upon request, each Party shall provide the other Party with evidence of the existence and maintenance of such insurance coverage. 

ARTICLE 12 
 TERM AND
TERMINATION 
 12.1 Term. This Agreement becomes effective as of the Effective Date and shall continue until the earliest of
(a) the termination of this Agreement in accordance with Section 12.2, (b) on a Product-by-Product and country-by-country basis, upon the expiration of the Royalty Term with regard to such Product in such country, (c) on an Promoter
Profile-by-Promoter Profile basis, upon the expiration of the applicable Evaluation Period for such Promoter Profile without exercise by Spark of the Spark Option with
respect to any Option Promoter selected pursuant to Section 3.8.3 from the final Synthetic Promoters resulting from Senti’s work under the Research Plan with the goal of generating Synthetic Promoters that have such
Promoter Profile and (d) expiration of the Research Term without selection pursuant to Section 3.8.3 of any Option Promoters (the “Term”). 

12.2 Termination. 

12.2.1 Termination for Convenience. Spark shall have the right to terminate this Agreement (with respect to any Promoter Profile
or Licensed Promoter or in its entirety) for convenience by providing [***] prior written notice to Senti (the “Notice Period”); provided, however, that if [***], then such Notice Period shall be [***]. 

  
 - 41 - 

 12.2.2 Termination for Material Breach. This Agreement (either in its entirety
or only in part, in the non-breaching Party’s discretion) may be terminated by a Party at any time during the Term upon written notice to the other Party if such other Party is in material breach of this
Agreement and has not cured such breach within [***]. Any such termination shall become effective at the end of such [***] period unless the breaching Party has cured such breach prior to the end of such period. Any right to terminate under this
Section 12.2.2 shall [***]. 
 12.2.3 Termination for Patent Challenge. Senti shall have the right to
terminate this Agreement, in the event that (a) Spark or its Affiliates commences, or assists any Third Party in commencing, any Patent Challenge with respect to any Senti Patent Right or claim thereof; or (b) any Sublicensee of
Spark commences any such Patent Challenge, and within [***] following the commencement thereof, such Patent Challenge is not withdrawn or Spark does not terminate its sublicense agreement with such party who commenced such Patent Challenge.
Notwithstanding the foregoing, Senti shall have no such right to terminate this Agreement as a result of (i) any Patent Challenge made by Spark or any of its Affiliates or Sublicensees as a defense in any lawsuit or administrative proceeding brought
by Senti, any of its Affiliates, or any of their respective licensees asserting the Patent Rights forming the basis for such claim or (ii) [***]; provided, that [***]. 

12.2.4 Termination for Bankruptcy. Either Party may terminate the Agreement upon written notice to the other Party, to the extent
permitted by applicable Law, if the other Party makes (a) a voluntary or involuntary general assignment of its assets for the benefit of creditors, and in the event of an involuntary assignment, such assignment is not dismissed within [***]
after the commencement thereof, (b) a petition in bankruptcy is filed by or against the other Party, and in the event of a petition filed against the other Party, such petition is not dismissed in [***], or (c) a receiver or trustee is
appointed for all or substantially all of the other Party’s property. 
 12.3 Effects of Termination. 

12.3.1 Termination by Senti for Cause or by Spark At Will. Upon any termination by Senti in accordance with
Section 12.2.2, Section 12.2.3 or Section 12.2.4, or by Spark in accordance with Section 12.2.1, the following shall apply: 

(a) all licenses and rights granted by Senti to Spark pursuant to this Agreement shall automatically terminate; 

(b) if such termination (i) is by Spark pursuant to Section 12.2.1 or by Senti pursuant to
Section 12.2.2 or Section 12.2.3, and (ii) occurs during the Research Term, then Spark shall pay for all unreimbursed costs (FTEs and Out-of-Pocket Costs) incurred with respect to activities completed under the Research Plan in accordance with Section 7.2 or the wind-down of the Research Program prior to the
effective date of termination, and any non-cancellable costs incurred in connection with such activities or arising from commitments made prior to notice of termination; and 

  
 - 42 - 

 (c) if any Product incorporating a terminated Licensed Promoter is in Clinical Trials or is
being Commercialized at the effective time of termination, upon written request from Senti provided within [***] of the effective date of termination, Spark shall consider, in its reasonable discretion, the grant of a Reversion License to Senti for
such Product. If Spark determines that it would be willing to grant such Reversion License, the Parties shall negotiate in good faith for a period of up to [***] after Spark’s receipt of Senti’s request to agree upon the terms of a
Reversion License for such Product, including appropriate financial payments to Spark. For clarity, any such Reversion License which includes a sublicense of intellectual property licensed by Spark from a Third Party will be subject to the
terms of such Third Party agreement, including any payment or other obligations or restrictions. [***]. Notwithstanding the foregoing and without limiting any other reasonable basis upon which Spark may not grant a Reversion License, it is
acknowledged and agreed that a determination by Spark not to grant a Reversion License due to Spark’s [***] shall be deemed reasonable. “Reversion License” shall mean, with respect to a terminated Product, a license under
intellectual property Controlled by Spark that Covers such Product to develop, manufacture and commercialize such Product in the applicable Licensed Field for which it was Developed by Spark. 

12.3.2 Termination by Spark for Cause. Upon any termination by Spark in accordance with Section 12.2.2 or
Section 12.2.4, all licenses and rights granted by Senti to Spark pursuant to this Agreement shall automatically terminate. 

12.3.3 [***]: 
 (a) [***].

 (b) [***]. 
 (c) [***].

 (d) [***]. 
 12.3.4 Scope
of Termination. For clarity, termination pursuant to Section 12.2.1 or Section 12.2.2 may apply to (a) this Agreement in its entirety, in which case
Section 12.3.1 or Section 12.3.2 (as applicable) shall apply to the entire Agreement, (b) [***], in which case Section 12.3.1 or Section 12.3.2
(as applicable) shall apply only to [***], or (c) [***], in which case Section 12.3.1 or Section 12.3.2 (as applicable) shall apply only to [***]. 

12.4 Accrued Obligations. Expiration or termination of this Agreement for any reason shall not release any Party of any obligation or
liability which, at the time of such expiration or termination, has already accrued or which is attributable to a period prior to such expiration or termination. 

12.5 Survival. 

12.5.1 The following provisions shall survive the expiration or termination of this Agreement: [***]. 

12.6 Non-exclusive Remedy. Termination of this Agreement shall be in addition to, and shall not
prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the
termination. 

  
 - 43 - 

 ARTICLE 13 

DISPUTE RESOLUTION 
 13.1
Governing Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, USA applicable to agreements made and to be performed entirely within such
state without regard to its conflicts of laws principles; provided that any matters relating to the construction or effect of any patent will be governed by the patent laws of the United States. This Agreement was prepared in the English
language, which language shall govern the interpretation of, and any dispute regarding, the terms of this Agreement. Each Party [***]. Notwithstanding the forgoing, nothing contained in this Agreement will deny any Party the right to seek injunctive
relief or other equitable relief from a court of competent jurisdiction applying the laws of the court in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any other
ongoing proceeding. EACH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY
OTHER TRANSACTION AGREEMENT. 
 13.2 Dispute Resolution. If any dispute or disagreement arises between Senti and Spark in respect
of this Agreement (other than with respect to any matter that is governed by Section 2.2.4), they shall follow the following procedures in an attempt to resolve the dispute or disagreement: 

13.2.1 The Party claiming that such a dispute exists shall give notice in writing to the other Party of the nature of the dispute (a
“Notice of Dispute”). 
 13.2.2 Within [***] of receipt of a Notice of Dispute, the Executive Officer of each Party shall
meet in person or by teleconference and exchange written summaries reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting, they shall use their reasonable efforts to resolve the dispute. 

13.2.3 If within [***] the dispute has not been resolved by the Executive Officers, or if, for any reason, the meeting described in
Section 13.2.2 has not been held within [***] of initial receipt of the Notice of Dispute, then the Parties agree that either Party may initiate litigation to resolve the dispute. 

13.3 Equitable Relief. Nothing in this Agreement shall limit the right of either Party to seek to obtain in any court of competent
jurisdiction any equitable or interim relief or provisional remedy, including injunctive relief. 
 ARTICLE 14 

MISCELLANEOUS 
 14.1
Waiver. No provision of the Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the
waiving Party. The waiver by any of the Parties of any breach of any provision hereof by another Party shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 

  
 - 44 - 

 14.2 Rights Cumulative. Except as expressly provided in this Agreement, no right or
remedy herein conferred upon or reserved to either Party is intended to be exclusive of any other right or remedy. 
 14.3 Notices.
All notices, instructions and other communications hereunder or in connection herewith shall be in writing, shall be sent to the address specified in this Section 14.3 and shall be: (a) delivered personally;
(b) sent via an internationally reputable express air courier service; or (c) sent by facsimile or e-mail transmission. Any such notice, instruction or communication shall be deemed to have been
delivered (i) upon receipt if delivered by hand; (ii) [***] after it is sent by internationally reputable express air courier service; or (iii) when transmitted with electronic confirmation of receipt, if transmitted by facsimile or e-mail (if such transmission is on a Business Day; otherwise, on the next Business Day following such transmission) and provided a confirmation copy is also sent by one of the methods set forth in (a) or (b).

 Notices to Senti shall be addressed to: 

Senti Biosciences, Inc. 
 2
Corporate Drive 
 South San Francisco, CA 94080 

Attention: [***] 
 With a copy
to: 
 Cooley LLP 
 3175
Hanover Street 
 Palo Alto, CA 94304 

Attention: Marya A. Postner 
 Notices to Spark
shall be addressed to: 
 Spark Therapeutics, Inc. 

3737 Market Street, Suite 1300 

Philadelphia, PA 19104 

Attention: [***] 
 Facsimile:
[***] 
 With a copy to: 

Hogan Lovells US LLP 
 390 Madison
Avenue 
 New York, NY 10017 

Attention: Adam H. Golden 

  
 - 45 - 

 Either Party may change its address by giving notice to the other Party in the manner provided above. 

14.4 Entire Agreement; Amendment. This Agreement (including all Exhibits and Schedules attached hereto) contains the complete
understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating to such subject matter, including (a) any and all term sheets and
non-binding proposals relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date and (b) the Confidentiality Agreement. No amendment, change
or addition to this Agreement will be effective or binding on either Party unless reduced to writing and duly executed on behalf of both Parties. 

14.5 Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable,
the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In
any such event, this Agreement shall be construed as if such clause or portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties
as expressed in this Agreement to the fullest extent permitted by Law. 
 14.6 Assignment. Neither this Agreement nor any right or
obligation hereunder may be assigned or otherwise transferred by any Party without the written consent of the other Party; provided, however, that (a) either Party may, without such consent, assign this Agreement, in whole or in
part, to any of its Affiliates and (b) any Party may, without such consent, assign this Agreement, in whole or in part in connection with a Change of Control or to any purchaser of all or substantially all of the assets of such Party to
which this Agreement relates, or any acquirer of all or substantially all of such Party’s capital stock, or to any successor corporation or entity resulting from any merger or consolidation of such Party with or into such corporation or entity;
provided that the Person to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement and a copy of such written agreement by such assignee shall be
provided to the non-assigning Party within [***] after such assignment. If either Party assigns this Agreement, in whole or in part, in accordance with clause (a) or (b) of this
Section 14.6, such Party shall remain primarily liable with respect to all obligations so assigned. Any purported assignment in violation of this Section 14.6 shall be void. The terms of this
Agreement shall be binding on and inure to the benefit of the permitted successors and permitted assigns of the Parties. 
 14.7
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Facsimile signatures and signatures
transmitted via PDF shall be treated as original signatures. 

  
 - 46 - 

 14.8 Force Majeure. Except with respect to payment of money, no Party shall be liable
to the other Party for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by earthquake, riot, civil commotion, war, terrorist acts, strike, flood, or
governmental acts or restriction, pandemic, or other cause that is beyond the reasonable control of the respective Party (“Force Majeure”). The Party affected by such Force Majeure will provide the other Party with full particulars
thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to
resume performance of its obligations as soon as practicable. If the performance of any such obligation under this Agreement is delayed owing to an event of Force Majeure for any continuous period of more than [***], the Parties will consult with
respect to an equitable solution, including the possibility of the termination of this Agreement. 
 14.9 Third Party Beneficiaries.
None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party other than the Indemnitees. No other Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such
provision have the right under this Agreement to make any claim in respect of any debt, liability or obligation (or otherwise) against either Party. 

14.10 Relationship of the Parties. The Parties agree that the relationship of Spark and Senti established by this Agreement is that of
independent contractors. Furthermore, the Parties agree that this Agreement does not, is not intended to, and shall not be construed to, establish an employment, agency, partnership or any other relationship. Except as may be specifically provided
herein, no Party shall have any right, power or authority, nor shall they represent themselves as having any authority to assume, create or incur any expense, liability or obligation, express or implied, on behalf of any other Party, or otherwise
act as an agent for any other Party for any purpose. 
 14.11 Performance by Affiliates. Either Party may use one or more of its
Affiliates to carry out its obligations and duties hereunder, and Affiliates of a Party are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of such Party and the
relevant Party shall remain liable hereunder for the prompt payment and performance of all their respective obligations hereunder. 
 14.12
Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees
that it will not export, directly or indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export
license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity in accordance with applicable Law. 

  
 - 47 - 

 14.13 Construction. Each Party acknowledges that it has been advised by counsel
during the course of negotiation of this Agreement, and, therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted. The headings,
captions and table of contents in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement. In construing this Agreement, except where the context requires otherwise, (a) use of the singular
includes the plural and vice versa; (b) the words “include” “including”, “includes” and “e.g.” mean “including without limitation”; (c) the word “or” is used in the inclusive
sense that is typically associated with the phrase “and/or”; (d) the words “herein,” “hereof” and “hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any particular
provision hereof; (e) the verb “will” shall be construed to have the same meaning and effect as the word “shall”; (f) use of any gender includes any other gender; (g) whenever this Agreement refers to a number of days,
such number shall refer to calendar days unless Business Days are specified; (h) references to a particular Law mean such Law as in effect as of the relevant time, including all rules and regulations thereunder and any successor Law in effect
as of the relevant time, and including the then-current amendments thereto; (i) references to a particular Person include such Person’s successors and assigns to the extent not prohibited by this Agreement; (j) a capitalized term not
defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; (k) the words “Dollar” and “dollar” and the symbol “$” mean
U.S. Dollars; (l) the word “notify” or “notice” means a notice in writing; (m) all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits or Schedules
of this Agreement and (n) references to any agreement (including this Agreement) are to the agreement as amended, modified, supplemented or replaced from time to time. 

  
 - 48 - 

 IN WITNESS WHEREOF, the Parties have entered into this Research Collaboration and License
Agreement as of the Effective Date. 
  

			
	SENTI BIOSCIENCES, INC.
		
	By:	 	 /s/ Curt Herberts

		 	Name: Curt A. Herberts III
		 	Title: COO and Acting CFO
	
	SPARK THERAPEUTICS, INC.
		
	By:	 	 /s/ Jeffrey Marrazzo

		 	Name: Jeffrey D. Marrazzo
		 	Title: CEO

 [Signature Page to Research Collaboration and License Agreement] 

 Exhibit A 

Option Field 
 [***]

 Exhibit B 

Promoter Profiles 

[***] 

 Exhibit C 

Research Plan 
 [***]

 Exhibit D 

[***] 

 Exhibit E 

Materials Transfer Letter 

[***] 

 Exhibit F-1 

Senti Press Release 
 *
* * 
  
 

 
 Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene 

Therapies 
 Collaboration combines Senti
Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver - 

Senti Bio is potentially eligible to receive upfront, opt-in and milestone payments exceeding $645 million

 South San Francisco, Calif., April 13, 2021 —Senti Biosciences, a leading gene circuit company, today announced a
collaboration and option agreement with Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to apply Senti Bio’s gene circuit technology to the development of next-generation precision gene therapies directed toward
specific cell types in the central nervous system (CNS), eye or liver. Created from novel and proprietary combinations of DNA sequences, gene circuits reprogram cells with biological logic to sense inputs, compute decisions and respond to their
environments for defined therapeutic applications. 
 Senti Bio has designed, built and tested thousands of sophisticated gene circuits to drive its
internal therapeutic pipeline and to deploy into multiple cell and gene therapy delivery modalities across diverse therapeutic areas. Senti Bio’s broad gene circuit technology platform includes high-throughput approaches to design and test
highly potent and specific Smart Sensors that are responsive to cell-type and/or cell-state specific biomarkers. These Smart Sensors include synthetic promoters, which are compact DNA sequences engineered to more precisely regulate the expression of
therapeutic genes. Spark Therapeutics will apply Senti Bio’s Smart Sensors gene circuit platform towards the goal of developing gene therapies that achieve cell type- or disease-selective expression of therapeutic payloads. 

 “We view gene circuits as a critical component of any advanced cell and gene therapy, regardless of
therapeutic area or delivery modality. This collaboration with Spark Therapeutics aligns with our goal of enabling truly dynamic therapies that have the ability to discriminate between certain cell types, selectively express various payloads, and
respond to diverse disease environments,” said Tim Lu, MD, PhD, chief executive officer of Senti Bio. “We are extremely impressed by the capabilities and know-how of Spark Therapeutics specifically
in the area of gene therapy, and we look forward to bringing our mutual expertise together under this collaboration to harness the power of gene circuits to develop gene therapies that are clinically meaningful to patients.” 

Under the terms of the agreement, Senti Bio will be responsible for designing, building, and testing cell type- and disease specific-synthetic promoters for
use in certain CNS, ocular or liver-directed gene therapies. Spark Therapeutics will receive the option to exclusively license a defined number of synthetic promoters emerging from the collaboration for use in developing gene therapy products in
specified indications. Upon option exercise, Spark Therapeutics will be responsible for conducting preclinical, clinical and commercialization activities for any gene therapy candidates that incorporate Senti Bio’s licensed synthetic promoters.

 Senti Bio will receive an upfront payment as well as funding to support its research activities, and upon option exercise will be eligible to receive an
option exercise payment as well as development, regulatory, and sales milestone payments in addition to royalties on a per product basis. The aggregate potential value of upfront, opt-in and milestone payments
to Senti Bio may exceed $645 million. 
 About Senti Bio 

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. We have built a synthetic
biology platform that enables us to program next-generation cell and gene therapies with what we refer to as “gene circuits.” These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells
with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic
effectiveness against a broad range of diseases that conventional medicines are unable to address. For more information, please visit the Senti Bio website at https://www.sentibio.com. 

### 

							
	Contact Senti Bio:	 		 		 	
				
	Curt Herberts, CFO, CBO	 		 		 	Denise Powell (Media)
				
	Email: corporate@sentibio.com	 		 		 	Email: denise@redhousecomms.com

 Find more information at sentibio.com 

Follow us on Linkedin: Senti Biosciences 
 Follow us on
Twitter: @SentiBio 

 Exhibit F-2 

Spark Press Release 
 *
* * 
  
 

 
 Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry- 

Leading Gene Therapy Research Platform 

Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark
Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver 
 Senti Bio is potentially eligible to receive
upfront, opt-in and milestone payments exceeding $645 million 
 PHILADELPHIA,
April 13, 2021 — Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of
genetic disease, today announced a collaboration and option agreement with Senti Biosciences, a leading gene circuit company, to apply Senti Bio’s gene circuit technology to the development of next-generation precision gene therapies directed
toward specific cell types in the central nervous system (CNS), eye or liver. Created from novel and proprietary combinations of DNA sequences, gene circuits reprogram cells with biological logic to sense inputs, compute decisions and respond to
their environments for defined therapeutic applications. 
 “As the leader in gene therapy, we are constantly evaluating emerging technologies to
complement our in-house expertise and welcome collaborations with innovators like Senti Bio, which we hope will further accelerate our efforts to unlock the full potential of gene therapy for patients living
with genetic disease,” said Joseph La Barge, chief business officer, Spark Therapeutics. 

 Senti Bio’s gene circuit technologies include high-throughput approaches to design and test highly
potent and specific Smart Sensors that are responsive to cell-type- and/or cell-state-specific biomarkers. These Smart Sensors include synthetic promoters, which are compact DNA sequences engineered to more precisely regulate the expression of
therapeutic genes. Spark Therapeutics will apply Senti Bio’s Smart Sensors gene circuit platform towards the goal of developing gene therapies that achieve cell type- or disease-selective expression of therapeutic payloads. 

“Breaking barriers for patients living with genetic disease requires evaluating opportunities to further our proven gene therapy platform, and we are
thrilled to collaborate with Senti Bio, which is at the forefront of using synthetic biology to engineer gene circuits to create therapies with enhanced therapeutic properties that increase efficacy, precision and control,” said Federico
Mingozzi, Ph.D., chief scientific officer, Spark Therapeutics. “We look forward to leveraging Senti Bio’s high-throughput synthetic promoter capabilities to develop novel gene therapies directed toward specific cell types in the central
nervous system, eye or liver.” 
 Under the terms of the agreement, Senti Bio will be responsible for designing, building and testing cell type- and
disease specific-synthetic promoters for use in developing certain CNS, eye or liver-directed gene therapies. Spark Therapeutics will receive the option to exclusively license a defined number of synthetic promoters emerging from the collaboration
for use in developing gene therapy products in specified indications. Upon option exercise, Spark Therapeutics will be responsible for conducting preclinical, clinical and commercialization activities for any gene therapy candidates that incorporate
Senti Bio’s licensed synthetic promoters. 
 Senti Bio will receive an upfront payment as well as funding to support its research activities, and upon
option exercise will be eligible to receive an option exercise payment as well as development, regulatory, and sales milestone payments in addition to royalties on a per product basis. The aggregate potential value of upfront, opt-in and milestone payments to Senti Bio may exceed $645 million. 
 Gene Therapy Partner of Choice 

Breaking barriers to unlock the full potential of gene therapy for patients living with genetic disease requires complementing our in-house expertise with collaborators across industry and academia. Spark Therapeutics has been at the forefront of gene therapy research for more than eight years, advancing more than a dozen clinical trials
against cell targets in the retina, liver and central nervous system. We strive to bring together the best and brightest technologies, scientific minds and innovators to bring more gene therapies to more patients living with genetic disease. 

 About Spark Therapeutics 

At Spark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challenge the
inevitability of genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. We currently have four programs in clinical trials. At Spark, a member of the Roche Group, we see the
path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn. 

Media Contact: 
 Kevin Giordano 

kevin.giordano@sparktx.com 
 (215)
294-9942 

 Exhibit G 

Data Package Template 

[***]EX-10.17

 Exhibit 10.17 

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant
treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

PUBLIC HEALTH SERVICE 

PATENT LICENSE AGREEMENT – EXCLUSIVE 

This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service
(“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug
Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). 

This Cover Page identifies the Parties to this Agreement: 

The U.S. Department of Health and Human Services, as represented by 

The National Cancer Institute 
 an
Institute or Center (hereinafter referred to as the “IC”) of the 
 NIH 

and 
 Senti Biosciences, Inc.,

 hereinafter referred to as the “Licensee”, 

having offices at 
 2 Corporate
Dr., First Floor, South San Francisco, CA 94080, 
 And operating under the laws of Delaware. 

Tax ID No.: 81-2944208 

 For the IC internal use only: 

License Number: [***] 

License Application Number: [***] 

Serial Number(s) of Licensed Patent(s) or Patent Application(s): 
  

	 	(a)	 US Provisional Patent Application No.: 62/643,015 

HHS Ref. No.: E-097-2018-0-US-01 

Filing Date: March 14, 2018 

Current Status: Converted to PCT 
  

	 	(b)	 PCT/US2019/022309 

HHS Ref. No.: E-097-2018-0-PCT-02 

Filing Date: March 14, 2019 

Current status: Expired 
  

	 	(c)	 United Arab Emirates Application No: P6001291/2020 

HHS Ref. No.: E-097-2018-0-AE-03 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(d)	 Australia Application No: 2019235926 

HHS Ref. No.: E-097-2018-0-AU-04 

Filing Date: September 2, 2020 

Current status: Pending 
  

	 	(e)	 Canada Application No: 3,093,567 

HHS Ref. No.: E-097-2018-0-CA-05 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(f)	 China No: 201980018105.0 

HHS Ref. No.: E-097-2018-0-CN-06 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(g)	 Eurasia Application No: 202092044 

HHS Ref. No.: E-097-2018-0-EA-07 

Filing Date: September 25, 2020 

Current status: Pending 
  

	 	(h)	 European Patent Application No: 19714007.2 

HHS Ref. No.: E-097-2018-0-EP-08 

Filing Date: October 14, 2020 

Current status: Pending 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 2 of 33	  	[SentiBio] Final [5-3-2021]

	 	(i)	 Israel Application No: 277078 

HHS Ref. No.: E-097-2018-0-IL-09 

Filing Date: September 1, 2020 

Current status: Pending 
  

	 	(j)	 India Application No: 202047039152 

HHS Ref. No.: E-097-2018-0-IN-10 

Filing Date: September 10, 2020 

Current status: Pending 
  

	 	(k)	 South Korea Application No: 2020-7029302 

HHS Ref. No.: E-097-2018-0-KR-11 

Filing Date: October 13, 2020 

Current status: Pending 
  

	 	(l)	 Mexico Application No: MX/a/2020/009472 

HHS Ref. No.: E-097-2018-0-MX-12 

Filing Date: September 10, 2020 

Current status: Pending 
  

	 	(m)	 New Zealand Application No: 767782 

HHS Ref. No.: E-097-2018-0-NZ-13 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(n)	 Saudi Arabia Application No: 520420134 

HHS Ref. No.: E-097-2018-0-SA-14 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(o)	 Singapore Application No: 11202008796V 

HHS Ref. No.: E-097-2018-0-SG-15 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(p)	 United States of America Application No: 16/980,205 

HHS Ref. No.: E-097-2018-0-US-16 

Filing Date: September 11, 2020 

Current status: Pending 
  

	 	(q)	 South Africa Application No: 2020/05571 

HHS Ref. No.: E-097-2018-0-ZA-17 

Filing Date: September 8, 2020 

Current status: Pending 

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A 

Public Benefit(s):The public interest would be well served by an exclusive license for this technology since therapies are needed for the
treatment of CD33 expressing cancers, among which are AML with a mortality rate of 10,000 per year and five-year survival of only 25%. AML is a rare disease and as a pediatric indication has inherent challenges in the development of new
therapies. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 3 of 33	  	[SentiBio] Final [5-3-2021]

 This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this
Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial
Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 4 of 33	  	[SentiBio] Final [5-3-2021]

 The IC and the Licensee agree as follows: 

 

	1.	 BACKGROUND 

  

	 	1.1	 In the course of conducting biomedical and behavioral research, the IC investigators made inventions
that may have commercial applicability. 

  

	 	1.2	 The IC warrants that, by assignment of rights from IC employees and other inventors, HHS,
on behalf of the Government, solely owns the rights in the Licensed Patent Rights as of the effective date of this Agreement. HHS also owns any tangible embodiments of the inventions claimed therein actually reduced to
practice by the IC. IC further warrants that to the best of its knowledge it has not granted and will not grant any licenses or rights within the Licensed Field of Use of this Agreement. 

 

	 	1.3	 The Secretary of HHS has delegated to the IC the authority to enter into this Agreement
for the licensing of rights to these inventions. 

  

	 	1.4	 The IC desires to transfer these inventions to the private sector through commercialization licenses to
facilitate the commercial development of products and processes for public use and benefit. 

  

	 	1.5	 The Licensee desires to acquire commercialization rights to certain of these inventions in order to
develop processes, methods, or marketable products for public use and benefit. 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “Additional License” means an exclusive, co-exclusive or non-exclusive commercial license that
includes the Licensed Patent Rights and is granted to a Third Party who is responsible for paying a share of patent expenses. [***] 

  

	 	2.2	 “Affiliate(s)” means a corporation or other business entity, which directly or indirectly is
controlled by or controls, or is under common control with the Licensee. For this purpose, the term “control” shall mean ownership of more than fifty percent (50%) of the voting stock or other ownership interest of the
corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity. 

 

	 	2.3	 “Benchmarks” mean the performance milestones that are set forth in Appendix D.

  

	 	2.4	 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

  

	 	2.5	 “CRADA” means a Cooperative Research and Development Agreement. 

 

	 	2.6	 “Fair Market Value” means the total amount or value expressed in U.S. dollars obtained by the
Licensee through the transfer or sale of its assets. 

  

	 	2.7	 “FDA” means the U.S. Food and Drug Administration, and any successor agency thereto.

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 5 of 33	  	[SentiBio] Final [5-3-2021]

	 	2.8	 “First Commercial Sale” means (a) with respect to a Licensed Product, the first
sale by or on behalf of the Licensee or any of its Affiliates or its sublicensees of such Licensed Product to a Third Party (other than a sublicensee) for end use of such Licensed Product in a regulatory
jurisdiction after regulatory approval has been granted for such Licensed Product in such regulatory jurisdiction or (b) the first practice of a Licensed Process by or on behalf of the Licensee or any of its Affiliates
or its sublicensees for a Third Party (other than a sublicensee), in each case (a) and (b) in exchange for cash or some equivalent to which value can be assigned for the purpose of determining Net Sales.

  

	 	2.9	 “Government” means the Government of the United States of America. 

 

	 	2.10	 “IND” means (a) an Investigational New Drug Application as defined in the Federal Food,
Drug, and Cosmetic Act and applicable regulations promulgated thereunder by the FDA or (b) any similar application filed in a regulatory jurisdiction outside the U.S. 

 

	 	2.11	 “Indication” means a class of human disease or condition for which a separate NDA
(including any extensions or supplements) is required to be filed with the FDA. For clarity, if an NDA is approved for a Licensed Product in a particular Indication and patient population, a label expansion for such
Licensed Product to include such Indication in a different patient population shall not be considered a separate Indication. 

  

	 	2.12	 “Licensed Fields of Use” means the fields of use identified in Appendix B.

  

	 	2.13	 “Licensed Patent Rights” means: 

 

	 	(a)	 Patent applications (including provisional patent applications and PCT patent applications) or patents listed
in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents; 

 

	 	(b)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in Paragraph 2.13(a): 

  

	 	(i)	 continuations-in-part of Paragraph 2.13(a); 

 

	 	(ii)	 all divisions and continuations of these continuations-in-part; 

 

	 	(iii)	 all patents issuing from these continuations-in-part, divisions, and continuations; 

 

	 	(iv)	 priority patent application(s) of Paragraph 2.13(a); and 

 

	 	(v)	 any reissues, reexaminations, and extensions of these patents; 

 

	 	(c)	 to the extent that the following contain one or more claims directed to the invention or inventions disclosed
in Paragraph 2.13(a): all counterpart foreign and U.S. patent applications and patents to Paragraphs 2.13(a) and 2.13(b), including those listed in Appendix A; and 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 6 of 33	  	[SentiBio] Final [5-3-2021]

	 	(d)	 Licensed Patent Rights shall not include Paragraph 2.13(b) or Paragraph 2.13(c) to the extent
that they contain one or more claims directed to new matter which is not the subject matter disclosed in Paragraph 2.13(a). 

  

	 	2.5	 “Licensed Processes” means processes which, in the course of being practiced, would be within
the scope of one or more valid and unexpired claims of the Licensed Patent Rights in the country in which such processes are practiced that have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of
a court of competent jurisdiction or revoked, disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

  

	 	2.6	 “Licensed Products” means tangible materials which, in the course of manufacture, use, sale,
or importation, would be within the scope of one or more valid and unexpired claims of the Licensed Patent Rights in the country of such manufacture, use, sale, or import, as applicable, that have not been held unpatentable, invalid or
unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction or revoked, disclaimed or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer or otherwise. 

 

	 	2.7	 “Licensed Territory” means the geographical area identified in Appendix B.

  

	 	2.8	 “NDA” means a New Drug Application of a Licensed Product filed with the FDA that
is required for marketing approval for such Licensed Product in the U.S. 

  

	 	2.9	 “Net Sales” means, with respect to any Licensed Product or Licensed Process, the
total gross receipts for sales of such Licensed Products or practice of such Licensed Processes by or on behalf of the Licensee or any of its Affiliates or its sublicensees to Third Parties, and from leasing,
renting, or otherwise making Licensed Products available to Third Parties without sale or other dispositions, whether invoiced or not, less the following: [***] No deductions shall be made for commissions paid to individuals, whether
they are with independent sales agencies or regularly employed by the Licensee, or any sublicensee, and on its payroll, or for the cost of collections. Notwithstanding the foregoing, sales among Licensee, its Affiliates, or
their respective sublicensees shall not be included in the calculation of Net Sales, unless the purchaser is an end user of the Licensed Product or Licensed Process. The supply of Licensed Product or practice of
Licensed Process as samples for charitable or promotional purposes, for use in non-clinical or clinical trials, or any test or other studies reasonably necessary to comply with any applicable laws, or as is otherwise normal and customary in
the industry shall not be included in the computation of Net Sales. 

  

	 	2.10	 [***] means [***]. 

  

	 	2.11	 [***] means [***]. 

  

	 	2.12	 [***] means [***].

  

	 	2.13	 “Practical Application” means to manufacture in the case of a composition or product, to
practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefits are to the extent permitted by law or
Government regulations available to the public on reasonable terms. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 7 of 33	  	[SentiBio] Final [5-3-2021]

	 	2.14	 “Pro Rata Share” means one of the following: 

 

	 	(a)	 in instances where the Additional License(s) granted by IC recover a pre-determined percentage of
patent costs, [***] which recover a pre-determined percentage of patent costs. For example, if IC has granted an Additional License [***], then the Pro Rata Share would be [***]; 

 

	 	(b)	 in instances where the Additional Licenses granted by IC recover a full pro rata share of patent
prosecution costs, [***] granted by IC which recover a full pro rata share of patent prosecution costs [***] granted by IC which recover a full pro rata share of patent prosecution costs. For example, if IC has
granted [***] which recover a full Pro Rata Share of patent prosecution costs, then the Pro Rata Share would be, [***], or [***]; or 

 

	 	(c)	 in instances where the Additional Licenses are granted according to the definition of both Paragraphs
2.23(a) and 2.23(b), the Pro Rata Share paid by Licensee will be the value derived from the Pro Rata Share [***] the value derived from the Pro Rata Share [***]. For example, if two (2) Additional Licenses
are granted wherein one (1) Additional License recovers [***] of patent prosecution costs and one (1) Additional License recovers a full pro rata share of patent prosecution costs, the Pro Rata Share would be
[(***]). 

  

	 	2.4	 “[***]” means, with respect to [***]. 

 

	 	2.5	 “[***]” means [***]. 

 

	 	2.6	 “Research License” means a nontransferable, nonexclusive license to make and to use the
Licensed Products or the Licensed Processes as defined by the Licensed Patent Rights for purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase. 

 

	 	2.7	 “Sublicensing Revenue” means the Fair Market Value of any consideration actually
received by Licensee from a Third Party as consideration for the grant of rights to such Third Party under the Licensed Patent Rights. Sublicensing Revenue includes upfront fees, license maintenance fees, and
milestone payments, and other payments received by Licensee in consideration for any rights granted to Licensed Patent Rights under a sublicense agreement, but excludes [***]. If Licensee receives any payments from a sublicensee
in consideration for the grant of a sublicense under the Licensed Patent Rights and under other intellectual property licensed to such sublicensee, Licensee shall fairly allocate such amounts among all licensed intellectual property,
and only the portion allocated to the Licensed Patent Rights will be included in Sublicensing Revenue. Any dispute between the parties related to the allocation of Sublicensing Revenue will be resolved in accordance with
Paragraph 14.5. 

  

	 	2.8	 “Third Party” means a person or entity other than (i) Licensee or any of its
Affiliates or sublicensees and (ii) IC. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 8 of 33	  	[SentiBio] Final [5-3-2021]

	3.	 GRANT OF RIGHTS 

 

	 	3.1	 The IC hereby grants and the Licensee accepts, subject to the terms and conditions of this
Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the
Licensed Fields of Use and to practice and have practiced any Licensed Process(es) in the Licensed Fields of Use. 

  

	 	3.2	 This Agreement confers no license or rights by implication, estoppel, or otherwise under any patent
applications or patents of the IC other than the Licensed Patent Rights regardless of whether these patents are dominant or subordinate to the Licensed Patent Rights. 

 

	4.	 SUBLICENSING 

  

	 	4.1	 [***], the Licensee may enter into sublicensing agreements under the Licensed Patent Rights;
provided that (a) the IC shall review and [***] within [***] following the receipt of Licensee’s notice therefor, (b) the IC shall [***] of the sublicense agreement, and (c) if the IC does [***]
sublicensing agreement within the [***] period, the IC shall [***] sublicensing agreement and the Licensee shall [***] sublicensing agreement. 

  

	 	4.2	 The Licensee agrees that any sublicenses granted by it shall provide that the obligations to the
IC of Paragraphs 5.1-5.4, 8.1, 10.1, 10.2, 12.5, and 13.8-13.10 of this Agreement shall be binding upon the sublicensee as if it were a party to this Agreement, to the extent applicable to the scope of the sublicense. The
Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements. 

  

	 	4.3	 Any sublicenses granted by the Licensee shall provide for the termination of the sublicense, or the
conversion to a license directly between the sublicensees and the IC, at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to the IC approval (not to be unreasonably
withheld, conditioned, or delayed) and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement, to the extent applicable to the scope of the sublicense. 

 

	 	4.4	 The Licensee agrees to forward to the IC a complete copy of each fully executed sublicense
agreement postmarked within [***] of the execution of the agreement; provided that Licensee may redact any commercially sensitive information which is not necessary for the IC to confirm (a) such sublicense agreement’s
compliance with the terms of this Agreement or (b) the sublicensing royalties due under this Agreement. To the extent permitted by law, the IC agrees to maintain each sublicense agreement in confidence.

  

	5.	 STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS 

 

	 	5.1	 

  

	 	(a)	 the IC reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable,
royalty-free license for the practice of all inventions licensed under the Licensed Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to
any existing or future treaty or agreement to which the Government is a signatory. Prior to the First Commercial Sale, at the IC’s reasonable request and to the extent available, the Licensee agrees to provide the
IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC internal, pre-clinical research use only, provided that IC may be responsible for reimbursing
Licensee for the cost and expense to manufacture and supply such Licensed Products and/or materials. IC may not transfer any such Licensed Products or materials supplied pursuant to this Paragraph 5.1(a) to any
organization, entity, or governmental agency other than IC without the prior written consent of Licensee; and 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 9 of 33	  	[SentiBio] Final [5-3-2021]

	 	(b)	 in the event that the Licensed Patent Rights are Subject Inventions made under CRADA, the
Licensee grants to the Government, pursuant to 15 U.S.C. §3710a(b)(1)(A), a nonexclusive, nontransferable, irrevocable, paid-up license to practice the Licensed Patent Rights or have the Licensed Patent Rights
practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential
within the meaning of 5 U.S.C. §552(b)(4) or which would be considered as such if it had been obtained from a non-Federal party. Prior to the First Commercial Sale, at the IC’s request and to the extent available, the
Licensee agrees to provide the IC with reasonable quantities of the Licensed Products or materials made through the Licensed Processes for IC internal research use only, provided that IC may be responsible
for reimbursing Licensee for the cost and expense to manufacture and supply such Licensed Products and/or materials. IC may not transfer any such Licensed Products or materials supplied pursuant to this Paragraph 5.1(b)
to any organization, entity, or governmental agency other than IC without the prior written consent of Licensee. 

  

	 	5.2	 To the extent required under 35 U.S.C. §204, as amended, the Licensee agrees that products used or
sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC.

  

	 	5.3	 The Licensee acknowledges that the IC may enter into future CRADAs under the Federal
Technology Transfer Act of 1986 that relate to the subject matter of this Agreement. The Licensee agrees not to unreasonably deny requests for a Research License from future collaborators with the IC when acquiring these
rights is necessary in order to make a CRADA project feasible. The IC shall notify Licensee of any such CRADA and Licensee may request an opportunity to join as a party to the proposed CRADA.

  

	 	5.4	 

  

	 	(a)	 in addition to the reserved license of Paragraph 5.1, the IC reserves the right to grant Research
Licenses directly or to require the Licensee to grant Research Licenses on reasonable terms. The purpose of these Research Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In
order to safeguard the Licensed Patent Rights, however, the IC shall consult with the Licensee before granting to commercial entities a Research License or providing to them research samples of materials made through the
Licensed Processes; and 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 10 of 33	  	[SentiBio] Final [5-3-2021]

	 	(b)	 in exceptional circumstances, and in the event that the Licensed Patent Rights are Subject Inventions
made under a CRADA, the Government, pursuant to 15 U.S.C. §3710a(b)(1)(B), retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use
the Licensed Patent Rights in the Licensed Field of Use on terms that are reasonable under the circumstances, or if the Licensee fails to grant this license, the Government retains the right to grant the license itself.
The exercise of these rights by the Government shall only be in exceptional circumstances and only if the Government determines: 

  

	 	(i)	 the action is necessary to meet health or safety needs that are not reasonably satisfied by the
Licensee; 

  

	 	(ii)	 the action is necessary to meet requirements for public use specified by Federal regulations, and these
requirements are not reasonably satisfied by the Licensee; or 

  

	 	(iii)	 the Licensee has failed to comply with an agreement containing provisions described in 15 U.S.C.
§3710a(c)(4)(B); and 

  

	 	(c)	 the determination made by the Government under this Paragraph 5.4 is subject to administrative appeal
and judicial review under 35 U.S.C. §203(b). 

  

	6.	 ROYALTIES AND REIMBURSEMENT 

 

	 	6.1	 The Licensee agrees to pay the IC a noncreditable, nonrefundable license issue royalty as set
forth in Appendix C. 

  

	 	6.2	 The Licensee agrees to pay the IC a nonrefundable minimum annual royalty as set forth in Appendix
C. 

  

	 	6.3	 The Licensee agrees to pay the IC earned royalties as set forth in Appendix C.

  

	 	6.4	 The Licensee agrees to pay the IC benchmark royalties as set forth in Appendix C.

  

	 	6.5	 The Licensee agrees to pay the IC sublicensing royalties as set forth in Appendix C.

  

	 	6.6	 A patent or patent application licensed under this Agreement shall cease to fall within the Licensed
Patent Rights for the purpose of computing earned royalty payments in any given country on the earliest of the dates that: 

  

	 	(a)	 the application has been abandoned and not continued; 

 

	 	(b)	 the patent expires or irrevocably lapses or has been revoked, disclaimed or admitted to be invalid or
unenforceable through reissue, re-examination, disclaimer or otherwise; or 

  

	 	(c)	 the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of
competent jurisdiction or administrative agency. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 11 of 33	  	[SentiBio] Final [5-3-2021]

	 	6.7	 No multiple royalties shall be payable because any Licensed Products or Licensed Processes are
covered by more than one of the Licensed Patent Rights. 

  

	 	6.8	 On sales of the Licensed Products by the Licensee made in other than an arm’s-length
transaction, the value of the Net Sales attributed under this Article 6 to this transaction shall be that which would have been received in an arm’s-length transaction in the same country, based on sales of like quantity and quality
products in the same country on or about the time of this transaction. 

  

	 	6.9	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive,
co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a pro rata share of patent expenses for the Licensed Patent Rights that are paid by the IC prior to the
effective date of the Additional License, pursuant to similar terms to those set forth for Licensee hereunder. With regard to expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and
patents included within the Licensed Patent Rights and paid by the IC prior to the effective date of this Agreement, the Licensee shall pay the IC, as an additional royalty, within [***] of the IC’s
submission of a statement and request for payment to the Licensee, an amount equivalent to [***] ($[***]). 

  

	 	6.10	 The IC shall use reasonable efforts to require any Third Party obtaining an exclusive,
co-exclusive or non-exclusive license under the Licensed Patent Rights pursuant to an Additional License to pay a pro rata share of patent expenses for the Licensed Patent Rights that are paid by the IC on or after to the
effective date of this Agreement, pursuant to similar terms to those set forth for Licensee hereunder. With regard to expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents
included within the Licensed Patent Rights and paid by the IC on or after the effective date of this Agreement or the effective date of the Additional License, whichever occurs first, the IC, at its sole option,
may require the Licensee: 

  

	 	(a)	 to pay the IC on an annual basis, within [***] of the IC’s submission of a statement and
request for payment, a royalty amount equivalent to the Pro Rata Share of these expenses paid during the previous calendar year(s); 

  

	 	(b)	 to pay the Pro Rata Share of these expenses directly to the law firm employed by the IC to handle
these functions. However, in this event, the IC and not the Licensee shall be the client of the law firm; or 

  

	 	(c)	 in limited circumstances, the Licensee may be given the right, but not the obligation, to assume
responsibility for the preparation, filing, prosecution, or maintenance of any patent application or patent included in the Licensed Patent Rights. In that event, the Licensee shall directly pay the attorneys or agents engaged to
prepare, file, prosecute, or maintain these patent applications or patents and shall provide the IC with copies of each invoice associated with these services as well as documentation that these invoices have been paid. 

 

	6.11	 The IC agrees, upon written request, to provide the Licensee with summaries of patent prosecution
invoices for which the IC has requested payment from the Licensee under Paragraphs 6.9 and 6.10. The Licensee agrees that all information provided by the IC related to patent prosecution costs shall be treated as
confidential commercial information and shall not be released to a Third Party except as required by law or a court of competent jurisdiction. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 12 of 33	  	[SentiBio] Final [5-3-2021]

	6.12	 The Licensee may elect to surrender its rights in any country of the Licensed Territory under any
of the Licensed Patent Rights upon [***] written notice to the IC and owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after [***] of the effective date of the written notice.

  

	7.	 PATENT FILING, PROSECUTION, AND MAINTENANCE 

 

	 	7.1	 Except as otherwise provided in this Article 7, the IC agrees to take responsibility for, but to consult
with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in the Licensed Patent Rights and shall furnish copies of relevant patent-related documents to the
Licensee, including drafts of any substantive filing or response at least [***] in advance of intended submission when practicable, and shall reasonably consider and implement Licensee’s comments thereto. 

 

	 	7.2	 If the IC decides not to prepare, file, prosecute, or maintain any patent applications or patents
included in the Licensed Patent Rights, and Licensee is in good standing on the payment of patent reimbursement royalties, the IC shall notify Licensee at least [***] prior to any filing, payment, or other deadlines when
practicable. In such case, the Licensee and any Third Party to an Additional License that is in good standing on the payment of patent reimbursement royalties shall promptly discuss which party shall have the right, but not the
obligation, to assume, at its own expense, the responsibility for the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in such Licensed Patent Rights. If Licensee elects to assume
such responsibility, it shall, on an ongoing basis, promptly furnish copies of all patent-related documents to the IC. In this event, the Licensee shall, subject to the prior approval of the IC, select registered patent
attorneys or patent agents to provide these services on behalf of the Licensee and the IC. The IC shall provide appropriate powers of attorney and other documents necessary to undertake this action to the patent attorneys or
patent agents providing these services. The Licensee and its attorneys or agents shall consult with the IC in all aspects of the preparation, filing, prosecution and maintenance of patent applications and patents included within the
Licensed Patent Rights and shall provide the IC sufficient opportunity to comment on any document that the Licensee intends to file or to cause to be filed with the relevant intellectual property or patent office

  

	 	7.3	 Each party shall promptly inform the other as to all matters that come to its attention that may affect the
preparation, filing, prosecution, or maintenance of the Licensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of the Licensed Patent
Rights, which comments and suggestions shall be considered by the other party. 

  

	8.	 RECORD KEEPING 

 

	 	8.1	 The Licensee agrees to keep accurate and correct records of the Licensed Products made, used,
sold, or imported and the Licensed Processes practiced under this Agreement appropriate to determine the amount of royalties due the IC. These records shall be retained for at least [***] following a given reporting period and
shall be available during normal business hours for inspection, at the expense of the IC, by an accountant or other designated auditor selected by the IC and reasonably acceptable to Licensee for the sole purpose of verifying
reports and royalty payments hereunder. The IC may conduct such audits no more than once per calendar year, and may inspect records from a particular reporting period only once. The accountant or auditor shall sign Licensee’s
standard confidentiality agreement prior to the inspection and shall only disclose to the IC information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or
underpayment in excess of [***] for any [***] period, then the Licensee shall reimburse the IC for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required
by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within [***] of the date the IC provides to the Licensee notice of the payment due. If any inspection shows an overpayment by Licensee for any
period, then Licensee shall be permitted to credit the amount of such overpayment against any future amounts owed by Licensee under this Agreement. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 13 of 33	  	[SentiBio] Final [5-3-2021]

	9.	 REPORTS ON PROGRESS, BENCHMARKS, SALES, AND PAYMENTS 

 

	 	9.1	 Prior to signing this Agreement, the Licensee has provided the IC with the Commercial
Development Plan in Appendix E, under which the Licensee intends to develop the Licensed Products or Licensed Processes with the intent of achieving the Practical Application. This Commercial Development Plan
is hereby incorporated by reference into this Agreement. Based on this plan, performance Benchmarks are determined as specified in Appendix D. 

  

	 	9.2	 The Licensee shall provide written annual reports on its product development progress or efforts to
commercialize under the Commercial Development Plan for the Licensed Fields of Use within [***] after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and
development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. The IC also encourages
these reports to include information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If [***], the Licensee shall [***]. In any annual report, the Licensee may
propose amendments to the Commercial Development Plan, acceptance of which by the IC may not be denied unreasonably. The Licensee agrees to [***] by the IC to evaluate the Licensee’s performance under this
Agreement. The Licensee may amend the Benchmarks at any time upon written approval by the IC. The IC shall not unreasonably withhold, condition or delay approval of any request of the Licensee to amend
the Commercial Development Plan, including the Benchmarks, and to extend the time periods of the Benchmarks if the request is supported by a reasonable showing by the Licensee of diligence in its performance under the
Commercial Development Plan and toward bringing the Licensed Products to the point of Practical Application as defined in 37 C.F.R. §404.3(d). The Licensee shall [***] in the plan originally submitted.

  

	 	9.3	 The Licensee shall report to the IC the dates for achieving Benchmarks specified in
Appendix D and the First Commercial Sale in each country in the Licensed Territory within [***] of such occurrences. 

  

	 	9.4	 The Licensee shall submit to the IC, within [***] after each calendar half-year ending
June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of the Licensed Products sold or Licensed Processes practiced by or on behalf
of the Licensee in each country within the Licensed Territory, the Net Sales, and the amount of royalty accordingly due. With each royalty report, the Licensee shall submit payment of earned royalties due. If no earned
royalties are due to the IC for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of the Licensee and shall include a listing of all deductions made under
Paragraph 2.18 to determine Net Sales made under Article 6 to determine royalties due. The royalty report shall also [***] for the Licensed Product(s) sold in the United States. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 14 of 33	  	[SentiBio] Final [5-3-2021]

	 	9.5	 The Licensee agrees to forward semi-annually to the IC a copy of the relevant portion of these
reports received by the Licensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to the IC by the Licensee for activities under the sublicense. 

 

	 	9.6	 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For
conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted in The Wall Street Journal on the day that the payment is due. Any loss of exchange, value, taxes, or other expenses
incurred in the transfer or conversion to U.S. dollars shall be paid entirely by the Licensee. The royalty report required by Paragraph 9.4 shall be mailed to the IC at its address for Agreement Notices indicated on the
Signature Page. 

  

	 	9.7	 The Licensee shall be solely responsible for determining if any tax on royalty income that Licensee
receives is owed outside the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments. 

  

	 	9.8	 Additional royalties may be assessed by the IC on any payment that is more than [***] overdue at the
rate of [***] per month or, if lower, the maximum rate permitted by applicable law. This [***] per month rate may be applied retroactively from the original due date until the date of receipt by the IC of the overdue payment and additional
royalties. The payment of any such additional royalties shall not prevent the IC from exercising any other rights it may have as a consequence of the lateness of any payment. 

 

	 	9.9	 All plans and reports required by this Article 9 and marked “confidential” by the Licensee
shall, to the extent permitted by law, be treated by the IC as commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by the IC under the Freedom of
Information Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification requirements of 45 C.F.R. §5.65(d). 

  

	10.	 PERFORMANCE 

  

	 	10.1	 The Licensee shall use its reasonable commercial efforts to bring the Licensed Products and the
Licensed Processes to Practical Application. “Reasonable commercial efforts” for the purposes of this provision shall include reasonable efforts to adhere to the Commercial Development Plan in Appendix E and to perform
the Benchmarks in Appendix D. The efforts of any Affiliate or a sublicensee shall be considered the efforts of the Licensee. 

  

	 	10.2	 Upon the First Commercial Sale, until the expiration or termination of this Agreement, the
Licensee shall use its reasonable commercial efforts to make the Licensed Products and the Licensed Processes reasonably accessible to the United States public. 

 

	 	10.3	 The Licensee agrees, after its First Commercial Sale, to make commercially reasonable quantities
of the Licensed Products or materials produced through the use of the Licensed Processes available to patient assistance programs in the U.S., if applicable. 

 

	 	10.4	 The Licensee agrees, after its First Commercial Sale and as part of its marketing and product
promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Products or medical aspects of the prophylactic and therapeutic uses of the Licensed Products.

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 15 of 33	  	[SentiBio] Final [5-3-2021]

	 	10.5	 The Licensee agrees to supply, upon the IC’s request, to the Mailing Address for
Agreement Notices indicated on the Signature Page, the Office of Technology Transfer, NIH with inert samples of the Licensed Products or the Licensed Processes or their packaging for educational and display purposes only.

  

	11.	 INFRINGEMENT AND PATENT ENFORCEMENT 

 

	 	11.1	 The IC and the Licensee agree to notify each other promptly of each infringement or possible
infringement of the Licensed Patent Rights in the Licensed Fields of Use, as well as, any facts which would be reasonably expected to affect the validity, scope, or enforceability of the Licensed Patent Rights of which either
party becomes aware. 

  

	 	11.2	 Pursuant to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee may:

  

	 	(a)	 bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid
claims in the Licensed Patent Rights; 

  

	 	(b)	 in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature
recoverable for the infringement; or 

  

	 	(c)	 settle any claim or suit for infringement of the Licensed Patent Rights in the Licensed Fields of Use
provided, however, that Licensee may not enter into any settlement that admits the invalidity of any Licensed Patent Rights without the prior written consent of the IC and appropriate Government authorities; and

  

	 	(d)	 if the Licensee desires to initiate a suit for patent infringement of the Licensed Patent Rights
in the Licensed Fields of Use, the Licensee shall notify the IC in writing. If the IC does not notify the Licensee of its intent to pursue legal action within [***], the Licensee shall be free to
initiate suit. The IC shall have a continuing right to be represented by its own counsel, at its own expense, in the suit. Upon the Licensee’s request, the Government may join in any such suit if necessary to avoid
dismissal of the suit. Should the Government be made a party to any such suit by motion or any other action by Licensee, [***] any reasonable costs, expenses, or fees which the Government incurs as a result of the motion or
other action. In all cases, the Licensee agrees to keep the IC reasonably apprised of the status and progress of any such litigation. Before the Licensee commences an infringement action, the Licensee shall notify the
IC and give careful consideration to the views of the IC and to any potential effects of the litigation on the public health in deciding whether to bring suit. If the Licensee elects not to bring an action to enforce any
Licensed Patent Rights against any infringement, the IC, at its option, may do so at its own expense. 

  

	 	11.3	 In the event that a declaratory judgment action alleging invalidity or non-infringement of any of the
Licensed Patent Rights shall be brought against the Licensee or raised by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee under Paragraph 11.2, pursuant to this Agreement and the
provisions of 35 U.S.C. Chapter 29 or other statutes, the Licensee may: 

  

	 	(a)	 defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in the
Licensed Patent Rights; 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 16 of 33	  	[SentiBio] Final [5-3-2021]

	 	(b)	 in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of
whatever nature recoverable for the infringement; and 

  

	 	(c)	 settle any claim or suit for declaratory judgment involving the Licensed Patent Rights, provided,
however, that Licensee may not enter into any settlement that admits the invalidity of any Licensed Patent Rights without the prior written consent of the IC. The IC and appropriate Government authorities shall
have the first right to take these actions and shall have a continuing right to intervene in the suit; and 

  

	 	(d)	 if the IC does not notify the Licensee of its intent to respond to the legal action within a
reasonable time, the Licensee shall be free to do so. The Licensee shall take no action to compel the Government either to initiate or to join in any declaratory judgment action. The Licensee may request the
Government to initiate or to join any such suit if necessary to avoid dismissal of the suit. Should the Government be made a party to any such suit by motion or any other action of the Licensee, the Licensee shall
reimburse the Government for any reasonable costs, expenses, or fees, which the Government incurs as a result of the motion or other action. If the Licensee elects not to defend against the declaratory judgment action, the
IC, at its option, may do so at its own expense. Licensee shall have the right to be represented by its own counsel, at its own expense, in any such defense by the IC. In all cases, the Licensee agrees to keep the
IC reasonably apprised of the status and progress of any litigation. Before the Licensee commences an infringement action, the Licensee shall notify the IC and give careful consideration to the views of the IC and
to any potential effects of the litigation on the public health in deciding whether to bring suit. 

  

	 	11.4	 In any action under Paragraphs 11.2 or 11.3, the expenses incurred by Licensee, including costs, fees,
attorney fees, and disbursements, shall be paid by the Licensee. The value of any recovery made by the Licensee through court judgment or settlement, after reimbursing Licensee’s expenses incurred in such action, shall be
[***]. 

  

	 	11.5	 The IC shall cooperate fully with the Licensee in connection with any action under Paragraphs
11.2 or 11.3. The IC agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by the Licensee. 

 

	12.	 NEGATION OF WARRANTIES AND INDEMNIFICATION 

 

	 	12.1	 The IC offers no warranties other than those specified in Article 1. 

 

	 	12.2	 The IC does not warrant the validity of the Licensed Patent Rights and makes no representations
whatsoever with regard to the scope of the Licensed Patent Rights, or that the Licensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of a Third Party.

  

	 	12.3	 THE IC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE
OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 17 of 33	  	[SentiBio] Final [5-3-2021]

	 	12.4	 The IC does not represent that it shall commence legal actions against any Third Party infringing
the Licensed Patent Rights. 

  

	 	12.5	 The Licensee shall indemnify and hold the IC, its employees, students, fellows, agents, and
consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage resulting from Third Party claims or demands to the extent arising
out of: 

  

	 	(a)	 the use by or on behalf of the Licensee, its sublicensees, directors, employees, or Third Parties
of any Licensed Patent Rights in the Licensed Fields of Use; or 

  

	 	(b)	 the design, manufacture, distribution, or use of any Licensed Products, Licensed Processes or
materials by the Licensee, or other products or processes developed by Licensee or its sublicensees in connection with or arising out of the Licensed Patent Rights, 

except in each case of Paragraphs 12.5(a) and (b) to the extent arising out of the IC’s breach of this Agreement or
the negligence or willful misconduct of the IC or any its employees, students, fellows, agents, or consultants. 
  

	 	12.6	 The Licensee agrees to maintain a liability insurance program consistent with sound business practice.

  

	13.	 TERM, TERMINATION, AND MODIFICATION OF RIGHTS 

 

	 	13.1	 This Agreement is effective when signed by all parties, unless the provisions of Paragraph 14.16 are not
fulfilled, and shall extend, on a Licensed Product-by-Licensed Product (or Licensed Process-by-Licensed Process) and country-by-country basis, to the expiration of the last to expire of the Licensed Patent Rights
that claims such Licensed Product (or Licensed Process) in such country unless sooner terminated as provided in this Article 13. 

  

	 	13.2	 In the event that the Licensee is in default in the performance of any material obligations under this
Agreement, including but not limited to the obligations listed in Paragraph 13.5, and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, the IC may terminate this
Agreement by written notice and pursue outstanding royalties owed through procedures provided by the Federal Debt Collection Act. 

  

	 	13.3	 In the event that the Licensee becomes insolvent, files a petition in bankruptcy, has such a petition
filed against it, determines to file a petition in bankruptcy, or receives notice of a Third Party’s intention to file an involuntary petition in bankruptcy, the Licensee shall immediately notify the IC in writing.

  

	 	13.4	 The Licensee shall have a unilateral right to terminate this Agreement or any licenses in any
country or territory by giving the IC sixty (60) days written notice to that effect. 

  

	 	13.5	 The IC shall specifically have the right to terminate or modify, at its option, this Agreement,
if the IC reasonably determines that the Licensee: 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 18 of 33	  	[SentiBio] Final [5-3-2021]

	 	(a)	 is not using commercially reasonable efforts to execute the Commercial Development Plan submitted with
its request for a license, as may be amended pursuant to Paragraph 9.2, and the Licensee cannot otherwise demonstrate to the IC’s satisfaction that the Licensee has taken, or can be expected to take within a reasonable
time, effective steps to achieve the Practical Application of the Licensed Products or the Licensed Processes; 

  

	 	(b)	 has not used commercially reasonable efforts to achieve the Benchmarks as may be modified under
Paragraph 9.2; 

  

	 	(c)	 has willfully made a false statement of, or willfully omitted a material fact in the license application or in
any report required by this Agreement; 

  

	 	(d)	 has committed a material breach of a covenant or agreement contained in this Agreement;

  

	 	(e)	 is not keeping the Licensed Products or the Licensed Processes reasonably available to the public
after commercial use commences; 

  

	 	(f)	 cannot reasonably satisfy unmet health and safety needs; 

 

	 	(g)	 cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless
waived; or 

  

	 	(h)	 has been found by a court of competent jurisdiction to have violated the Federal antitrust laws in connection
with its performance under this Agreement. 

  

	 	13.6	 In making the determination referenced in Paragraph 13.5, the IC shall take into account the normal
course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by the Licensee under Paragraph 9.2. Prior to invoking termination or modification of this
Agreement under Paragraph 13.5, the IC shall give written notice to the Licensee providing the Licensee specific notice of, and a ninety (90) day opportunity to respond to, the IC’s concerns as to the
items referenced in Paragraph 13.5(a)-13.5(g). If the Licensee fails to reasonably alleviate the IC’s concerns as to the items referenced in Paragraph 13.5(a)-13.5(g) or fails to develop a corrective action plan and initiate such
corrective action plan to the IC’s reasonable satisfaction, the IC may terminate this Agreement upon written notice to the Licensee. 

 

	 	13.7	 When the public health and safety so require, and after providing the Licensee a [***] opportunity to
respond, the IC shall have the right to require the Licensee to grant sublicenses to responsible applicants, on reasonable terms, in any Licensed Fields of Use under the Licensed Patent Rights, unless the Licensee
can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of the Licensed Patent Rights. The IC shall not require the granting of a sublicense
unless the responsible applicant has first negotiated in good faith with the Licensee. 

  

	 	13.8	 The IC reserves the right according to 35 U.S.C. §209(d)(3) to terminate or modify this
Agreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by the
Licensee. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 19 of 33	  	[SentiBio] Final [5-3-2021]

	 	13.9	 Within [***] of receipt of written notice of the IC’s [***] to modify or terminate this
Agreement, the Licensee may, consistent with the provisions of 37 C.F.R. §404.11, appeal the decision by written submission to the designated IC official or designee. The decision of the designated IC official or
designee shall be the final agency decision. The Licensee may thereafter exercise any and all administrative or judicial remedies that may be available. 

 

	 	13.10	 Within [***] of expiration or termination of this Agreement under this Article 13, a final report shall
be submitted by the Licensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to the IC shall become immediately due and payable upon
termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with the IC pursuant to Paragraph 4.3. Unless otherwise specifically provided for under this
Agreement, upon termination or expiration of this Agreement, the Licensee shall return all Licensed Products, or other IC-provided materials included within the Licensed Patent Rights to the IC or
provide the IC with written certification of the destruction thereof. The Licensee may not be granted additional IC licenses if the final reporting requirement is not fulfilled. 

 

	14.	 GENERAL PROVISIONS 

 

	 	14.1	 Neither party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right by such party or excuse a similar subsequent failure to perform any
of these terms or conditions by the other party. 

  

	 	14.2	 This Agreement constitutes the entire agreement between the parties relating to the subject matter of
the Licensed Patent Rights, the Licensed Products and the Licensed Processes, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by this
Agreement. 

  

	 	14.3	 The provisions of this Agreement are severable, and in the event that any provision of this
Agreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of this Agreement.

  

	 	14.4	 If either party desires a modification to this Agreement, the parties shall, upon reasonable notice of
the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to this Agreement or
their designees. 

  

	 	14.5	 The construction, validity, performance, and effect of this Agreement shall be governed by Federal law
as applied by the Federal courts in the District of Columbia. 

  

	 	14.6	 All Agreement notices required or permitted by this Agreement shall be in writing and given by
prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address
as may be designated in writing by such other party. Agreement notices shall be considered timely if such notices are received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal
Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be
acceptable as proof of timely mailing. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 20 of 33	  	[SentiBio] Final [5-3-2021]

	 	14.7	 This Agreement shall not be assigned or otherwise transferred (including any transfer by legal process
or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court), except to the Licensee’s Affiliate(s) (for which the consent of IC shall not be required), without the
prior written consent of the IC, not to be unreasonably withheld, conditioned or delayed. For any assignment other than to an Affiliate the IC will have a period of [***] from the date that it receives written notice from the
Licensee of a proposed assignment, to approve or reject the proposed assignment and such approval shall not be unreasonably withheld; the approval or rejection must be in writing and delivered to Licensee’s official address for
Agreement notices. If the IC does not reject the proposed assignment within the [***] period, the IC shall be deemed to have given its approval of such assignment and the Licensee shall have the right to enter into such
assignment agreement. The parties agree that the identity of the parties is material to the formation of this Agreement and that the obligations under this Agreement are nondelegable. In the event that the IC approves a proposed
assignment, the Licensee shall [***] for any assignment of this Agreement, within [***] of the assignment (it being understood that [***]). 

  

	 	14.8	 The Licensee agrees in its use of any IC-supplied materials to comply with all applicable
statutes, regulations, and guidelines, including NIH and HHS regulations and guidelines. The Licensee agrees not to use the materials for research involving human subjects or clinical trials in the United States without
complying with 21 C.F.R. Part 50 and 45 C.F.R. Part 46. The Licensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying the IC, in writing, of the
research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to the IC of such research involving human subjects or clinical trials outside of the United States shall
be given no later than [***] prior to commencement of the research or trials. 

  

	 	14.9	 The Licensee acknowledges that it is subject to and agrees to abide by the United States laws and
regulations (including the Export Administration Act of 1979 and Arms Export Control Act) controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may
require a license from the appropriate agency of the U.S. Government or written assurances by the Licensee that it shall not export these items to certain foreign countries without prior approval of this agency. The IC neither
represents that a license is or is not required or that, if required, it shall be issued. 

  

	 	14.10	 The Licensee agrees to mark the Licensed Products or their packaging sold in the United States
with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status, to the extent required by applicable laws. All the Licensed Products manufactured in, shipped to, or sold in other countries shall be marked
in a manner necessary to preserve the IC’s patent rights in those countries. 

  

	 	14.11	 By entering into this Agreement, the IC does not directly or indirectly endorse any product or
service provided, or to be provided, by the Licensee whether directly or indirectly related to this Agreement. The Licensee shall not state or imply that this Agreement is an endorsement by the Government, the
IC, any other Government organizational unit, or any Government employee. Additionally, the Licensee shall not use the names of the IC, the FDA or the HHS or the Government or their employees
in any advertising, promotional, or sales literature without the prior written approval of the IC. 

  

	 	14.12	 The parties agree to attempt to settle amicably any controversy or claim arising under this Agreement or
a breach of this Agreement, except for appeals of modifications or termination decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or
designee, whose decision shall be considered the final agency decision. Thereafter, the Licensee may exercise any administrative or judicial remedies that may be available. 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 21 of 33	  	[SentiBio] Final [5-3-2021]

	 	14.13	 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person
any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the source
of the grant. 

  

	 	14.14	 Any formal recordation of this Agreement required by the laws of any Licensed Territory as a
prerequisite to enforceability of the Agreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by the Licensee at its expense, and appropriately verified proof of recordation shall be promptly
furnished to the IC. 

  

	 	14.15	 Paragraphs 4.3, 8.1, 9.5-9.8 (solely with respect to payments incurred but not yet paid prior to the effective
date of expiration or termination), 12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of this Agreement shall survive termination of this Agreement. 

  

	 	14.16	 The terms and conditions of this Agreement shall, at the IC’s sole option, be considered by
the IC to be withdrawn from the Licensee’s consideration and the terms and conditions of this Agreement, and the Agreement itself to be null and void, unless this Agreement is executed by the Licensee
and a fully executed original is received by the IC within [***] from the date of the IC’s signature found at the Signature Page. 

SIGNATURES BEGIN ON NEXT PAGE 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 22 of 33	  	[SentiBio] Final [5-3-2021]

 NIH PATENT LICENSE AGREEMENT – EXCLUSIVE 

SIGNATURE PAGE 
 For the IC: 

 

			
	 s/ Richard U. Rodriguez-S
	  	 5-14-21

	Richard U. Rodriguez, M.B.A.	  	Date
	Associate Director	  	
	Technology Transfer Center, NCI	  	
	National Institutes of Health	  	

 Mailing Address or E-mail Address for Agreement notices and reports: 

License Compliance and Administration 
 Monitoring &
Enforcement 
 Office of Technology Transfer 
 National
Institutes of Health 
 6011 Executive Boulevard, Suite 325 

Rockville, Maryland 20852-3804 U.S.A. 
 E-mail:
LicenseNotices_Reports@mail.nih.gov 
 For the Licensee (Upon, information and belief, the undersigned expressly certifies or affirms that the
contents of any statements of the Licensee made or referred to in this document are truthful and accurate.): 
  

			
	by:	  	
		
	 /s/ Curt Herberts
	  	 5-17-2021

	Signature of Authorized Official	  	Date
		
	 Curt Herberts
	  	
	Printed Name	  	
		
	 COO and Acting CFO
	  	
	Title	  	

 I. Official and Mailing Address for Agreement notices: 

 

					
		 	   [***]
	  	
		 	  Name	  	
		 	   [***]
	  	
		 	  Title	  	
			
		 	  [***]	  	
		 		  	

 II. Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty
payments) 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 23 of 33	  	[SentiBio] Final [5-3-2021]

					
			
		 	  [***]	  	

 Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions,
under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001
(criminal liability including fine(s) or imprisonment). 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 24 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX A – PATENT(S) OR PATENT APPLICATION(S) 

Patent(s) or Patent Application(s): 
  

	 	(a)	 US Provisional Patent Application No.: 62/643,015 

HHS Ref. No.: E-097-2018-0-US-01 

Filing Date: March 14, 2018 

Current Status: Converted to PCT 
  

	 	(b)	 PCT/US2019/022309 

HHS Ref. No.: E-097-2018-0-PCT-02 

Filing Date: March 14, 2019 

Current status: Expired 
  

	 	(c)	 United Arab Emirates Application No: P6001291/2020 

HHS Ref. No.: E-097-2018-0-AE-03 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(d)	 Australia Application No: 2019235926 

HHS Ref. No.: E-097-2018-0-AU-04 

Filing Date: September 2, 2020 

Current status: Pending 
  

	 	(e)	 Canada Application No: 3,093,567 

HHS Ref. No.: E-097-2018-0-CA-05 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(f)	 China No: 201980018105.0 

HHS Ref. No.: E-097-2018-0-CN-06 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(g)	 Eurasia Application No: 202092044 

HHS Ref. No.: E-097-2018-0-EA-07 

Filing Date: September 25, 2020 

Current status: Pending 
  

	 	(h)	 European Patent Application No: 19714007.2 

HHS Ref. No.: E-097-2018-0-EP-08 

Filing Date: October 14, 2020 

Current status: Pending 
  

	 	(i)	 Israel Application No: 277078 

HHS Ref. No.: E-097-2018-0-IL-09 

Filing Date: September 1, 2020 

Current status: Pending 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 25 of 33	  	[SentiBio] Final [5-3-2021]

	 	(j)	 India Application No: 202047039152 

HHS Ref. No.: E-097-2018-0-IN-10 

Filing Date: September 10, 2020 

Current status: Pending 
  

	 	(k)	 South Korea Application No: 2020-7029302 

HHS Ref. No.: E-097-2018-0-KR-11 

Filing Date: October 13, 2020 

Current status: Pending 
  

	 	(l)	 Mexico Application No: MX/a/2020/009472 

HHS Ref. No.: E-097-2018-0-MX-12 

Filing Date: September 10, 2020 

Current status: Pending 
  

	 	(m)	 New Zealand Application No: 767782 

HHS Ref. No.: E-097-2018-0-NZ-13 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(n)	 Saudi Arabia Application No: 520420134 

HHS Ref. No.: E-097-2018-0-SA-14 

Filing Date: September 13, 2020 

Current status: Pending 
  

	 	(o)	 Singapore Application No: 11202008796V 

HHS Ref. No.: E-097-2018-0-SG-15 

Filing Date: September 9, 2020 

Current status: Pending 
  

	 	(p)	 United States of America Application No: 16/980,205 

HHS Ref. No.: E-097-2018-0-US-16 

Filing Date: September 11, 2020 

Current status: Pending 
  

	 	(q)	 South Africa Application No: 2020/05571 

HHS Ref. No.: E-097-2018-0-ZA-17 

Filing Date: September 8, 2020 

Current status: Pending 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 26 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX B – LICENSED FIELDS OF USE AND TERRITORY 

 

	I.	 Licensed Fields of Use: 

 

	 	1.	 The development of a CD33-specific logic-gated CAR-based immunotherapy using autologous human T cells
transduced with lentiviral vectors, wherein the viral transduction leads to the expression of a CAR that targets CD33 (comprised of the CD33-binding domain referenced as Hu195 or hP67.6 in the invention as well as an intracellular signaling domain),
for the prophylaxis or treatment of CD33-expressing cancers. [***] 

  

	 	2.	 The development of a CD33-specific logic-gated CAR-based immunotherapy using allogeneic human NK cells
transduced with retroviral vectors, including but not limited to lentiviral vectors, wherein the viral transduction leads to the expression of a CAR that targets CD33 (comprised of the CD33-binding domain referenced as Hu195 or hP67.6 in the
invention as well as an intracellular signaling domain), for the prophylaxis or treatment of CD33-expressing cancers. [***] 

  

	II.	 Licensed Territory:  

Worldwide 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 27 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX C – ROYALTIES 

Royalties: 
 I. The Licensee agrees to pay to the IC a
noncreditable, nonrefundable license issue royalty in the amount of one hundred and fifty thousand dollars ($150,000.00) [***]. 

  

					
	[***].	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 28 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX D – BENCHMARKS AND PERFORMANCE 

[***] 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 29 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX E – COMMERCIAL DEVELOPMENT PLAN 

[***] 
 [***] 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 30 of 33	  	[SentiBio] Final [5-3-2021]

 Appendix F – Example Royalty Report 

Required royalty report information includes: 
  

	•	 	 License reference number (L-XXX-200X/0) 

 

	•	 	 Reporting period 

  

	•	 	 Catalog number and units sold of each Licensed Product (domestic and foreign) 

 

	•	 	 Gross Sales per catalog number per country 

 

	•	 	 Total Gross Sales 

  

	•	 	 Itemized deductions from Gross Sales 

 

	•	 	 Total Net Sales 

  

	•	 	 Earned Royalty Rate and associated calculations 

 

	•	 	 Gross Earned Royalty 

  

	•	 	 Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made 

 

	•	 	 Net Earned Royalty due 

Example 
  

													
	 Catalog Number
	  	 Product
Name
	  	 Country
	  	Units
Sold	 	  	Gross
Sales
(US$)	 
	 1
	  	A	  	US	  	 	250	 	  	 	62,500	 
	 1
	  	A	  	UK	  	 	32	 	  	 	16,500	 
	 1
	  	A	  	France	  	 	25	 	  	 	15,625	 
	 2
	  	B	  	US	  	 	0	 	  	 	0	 
	 3
	  	C	  	US	  	 	57	 	  	 	57,125	 
	 4
	  	D	  	US	  	 	12	 	  	 	1,500	 

  

					
	 Total Gross Sales
	  	 	153,250	 
	 Less Deductions:
	  			
	 Freight
	  	 	3,000	 
	 Returns
	  	 	7,000	 
	 Total Net Sales
	  	 	143,250	 
	 Royalty Rate
	  	 	8	% 
	 Royalty Due
	  	 	11,460	 
	 Less Creditable Payments
	  	 	10,000	 
	 Net Royalty Due
	  	 	1,460	 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 31 of 33	  	[SentiBio] Final [5-3-2021]

 APPENDIX G – ROYALTY PAYMENT OPTIONS 

New Payment Options Effective March 2018 

The License Number MUST appear on payments, reports and correspondence. 

Credit and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the U.S.
Treasury web site located at: https://www.pay.gov/public/form/start/28680443. 
 Automated Clearing House (ACH) for payments through U.S. banks
only 
 The IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH
payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443. Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site. 

Electronic Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via Electronic
Funds Wire Transfer sender MUST supply the following information within the transmission: 
 Drawn on a U.S. bank account via FEDWIRE: 

Please provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND. 

[***] 
 Agency Contacts: Office of Technology
Transfer (OTT) [***] 
 Drawn on a foreign bank account via FEDWIRE: 

The following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD). 

Should your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable. 

[***] 
 Agency Contacts: 

Office of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov 

Checks 
 All checks should be made payable to
“NIH Patent Licensing” 
 Checks drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following
address: 
 [***] 
 Checks drawn on a U.S.
bank account and sent by overnight or courier should be sent to the following address: 
 [***] 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 32 of 33	  	[SentiBio] Final [5-3-2021]

 Checks drawn on a foreign bank account should be sent directly to the following address: 

[***] 

  

					
	[***]	  	CONFIDENTIAL	  	NIH Patent License Agreement--Exclusive Model 10-
			
	2015	  	Page 33 of 33	  	[SentiBio] Final [5-3-2021]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]